

1  
2  
3 **Mitochondrial respiratory states and rates:**  
4 **Building blocks of mitochondrial physiology Part 1**

5 **COST Action CA15203 MitoEAGLE preprint** Version: 2018-08-22(40)

6 Corresponding author: Gnaiger E

7 Co-authors:

8 Aasander Frostner E, Abumrad NA, Acuna-Castroviejo D, Ahn B, Ali SS, Alves MG, Amati  
9 F, Aral C, Arandarčikaitė O, Bailey DM, Bajpeyi S, Bakker BM, Bastos Sant'Anna Silva AC,  
10 Battino M, Bazil J, Beard DA, Bednarczyk P, Ben-Shachar D, Bergdahl A, Bernardi P,  
11 Bishop D, Blier PU, Boetker HE, Boros M, Borsheim E, Borutaitė V, Bouillaud F, Boutbir J,  
12 Breton S, Brown DA, Brown GC, Brown RA, Brozinick JT, Buettner GR, Burtscher J,  
13 Calabria E, Calbet JA, Calzia E, Cannon DT, Canto AC, Cardoso LHD, Carvalho E, Casado  
14 Pinna M, Cassina AM, Castro L, Cavalcanti-de-Albuquerque JP, Cervinkova Z, Chaurasia B,  
15 Chen Q, Chicco AJ, Chinopoulos C, Chowdhury SK, Clementi E, Coen PM, Coker RH,  
16 Collin A, Crisóstomo L, Di Marcello M, Darveau CA, Das AM, Dash RK, Davis MS, De  
17 Palma C, Dembinska-Kiec A, Dias TR, Distefano G, Doerrier C, Drahota Z, Dubouchaud H,  
18 Duchon MR, Dumas JF, Durham WJ, Dymkowska D, Dyrstad SE, Dzialowski EM, Ehinger J,  
19 Elmer E, Endlicher R, Engin AB, Fell DA, Ferko M, Ferreira JCB, Ferreira R, Fessel JP,  
20 Filipovska A, Fisar Z, Fischer M, Fisher G, Fisher JJ, Fornaro M, Galkin A, Gan Z, Garcia-  
21 Roves PM, Garcia-Souza LF, Garipi E, Garlid KD, Garrabou G, Garten A, Gastaldelli A,  
22 Genova ML, Giovarelli M, Gonzalez-Armenta JL, Gonzalo H, Goodpaster BH, Gorr TA,  
23 Gourlay CW, Granata C, Grefte S, Gueguen N, Haas CB, Haavik J, Haendeler J, Hamann A,  
24 Han J, Hancock CR, Hand SC, Hargreaves IP, Harrison DK, Heales SJR, Hellgren KT,  
25 Hepple RT, Hernansanz-Agustin P, Hickey AJ, Hoel F, Holland OJ, Holloway GP, Hoppel  
26 CL, Houstek J, Hunger M, Iglesias-Gonzalez J, Irving BA, Iyer S, Jackson CB, Jadiya P, Jang  
27 DH, Jang YC, Jansen-Dürr P, Jespersen NR, Jha RK, Jurk D, Kaambre T, Kaczor JJ,  
28 Kainulainen H, Kandel SM, Kane DA, Kappler L, Karabatsiakos A, Karkucinska-  
29 Wieckowska A, Keijer J, Keppner G, Khamoui AV, Klingenspor M, Komlodi T, Koopman  
30 WJH, Kopitar-Jerala N, Kowaltowski AJ, Krajcova A, Krako Jakovljevic N, Kristal BS,  
31 Kuang J, Kucera O, Kwak HB, Kwast K, Labieniec-Watala M, Lai N, Land JM, Lane N,  
32 Laner V, Lanza IR, Larsen TS, Lavery GG, Lee HK, Leeuwenburgh C, Lemieux H, Lerfall J,  
33 Li PA, Liu J, Lucchinetti E, Macedo MP, MacMillan-Crow LA, Makrecka-Kuka M, Malik A,  
34 Markova M, Martin DS, Mazat JP, McKenna HT, Menze MA, Meszaros AT, Methner A,  
35 Michalak S, Moellering DR, Moiso N, Molina AJA, Montaigne D, Moore AL, Moreau K,  
36 Moreno-Sánchez R, Moreira BP, Mracek T, Muntane J, Muntean DM, Murray AJ, Nair KS,  
37 Nemeš M, Neuffer PD, Neuzil J, Newsom S, Nozickova K, O'Brien KA, O'Gorman D,  
38 Oliveira MF, Oliveira MT, Oliveira PF, Oliveira PJ, Orynbayeva Z, Osiewacz HD, Pak YK,  
39 Pallotta ML, Palmeira CM, Parajuli N, Passos JF, Patel HH, Pecina P, Pelnena D, Pereira da  
40 Silva Grilo da Silva F, Perez Valencia JA, Pesta D, Petit PX, Pettersen IKN, Pichaud N, Piel  
41 S, Pietka TA, Pino MF, Pirkmajer S, Porter C, Porter RK, Pranger F, Prochownik EV,  
42 Pulnilkunnit T, Puskarich MA, Puurand M, Quijano C, Radenkovic F, Radi R, Ramzan R,  
43 Rattan S, Reboredo P, Renner-Sattler K, Robinson MM, Roden M, Rodríguez-Enriquez S,  
44 Rohlena J, Rolo AP, Ropelle ER, Røslund GV, Rossiter HB, Rybacka-Mossakowska J, Saada  
45 A, Safaei Z, Salin K, Salvadego D, Sandi C, Sanz A, Sazanov LA, Scatena R, Schartner M,

46 Scheibye-Knudsen M, Schilling JM, Schlattner U, Schönfeld P, Schwarzer C, Scott GR,  
 47 Shabalina IG, Sharma P, Sharma V, Shevchuk I, Siewiera K, Silber AM, Silva AM, Sims CA,  
 48 Singer D, Skolik R, Smenes BT, Smith J, Soares FAA, Sobotka O, Sokolova I, Sonkar VK,  
 49 Sowton AP, Sparagna GC, Sparks LM, Spinazzi M, Stankova P, Stary C, Stiban J, Stier A,  
 50 Stocker R, Sumbalova Z, Suravajhala P, Swerdlow RH, Swiniuch D, Szabo I, Szewczyk A,  
 51 Tanaka M, Tandler B, Tarnopolsky MA, Tavernarakis N, Tepp K, Thyfault JP, Tomar D,  
 52 Towheed A, Tretter L, Trifunovic A, Trivigno C, Tronstad KJ, Trougakos IP, Tyrrell DJ,  
 53 Urban T, Valentine JM, Velika B, Vendelin M, Vercesi AE, Victor VM, Vieyra A Villena JA,  
 54 Vitorino RMP, Vogt S, Volani C, Votion DM, Vujacic-Mirski K, Wagner BA, Ward ML,  
 55 Warnsmann V, Wasserman DH, Watala C, Wei YH, Wieckowski MR, Williams C,  
 56 Wohlgemuth SE, Wohlwend M, Wolff J, Wüst RCI, Yokota T, Zablocki K, Zaugg K, Zaugg  
 57 M, Zhang Y, Zhang YZ, Zischka H, Zorzano A

58  
 59 **Updates and discussion:**

60 [http://www.mitoeagle.org/index.php/MitoEAGLE\\_preprint\\_2018-02-08](http://www.mitoeagle.org/index.php/MitoEAGLE_preprint_2018-02-08)

61 Correspondence: Gnaiger E

62 *Chair COST Action CA15203 MitoEAGLE* – <http://www.mitoeagle.org>

63 *Department of Visceral, Transplant and Thoracic Surgery, D. Swarovski Research*  
 64 *Laboratory, Medical University of Innsbruck, Innrain 66/4, A-6020 Innsbruck, Austria*

65 *Email: mitoeagle@i-med.ac.at; Tel: +43 512 566796, Fax: +43 512 566796 20*  
 66

67 **Abstract - Executive summary**

68 **1. Introduction** – Box 1: In brief: Mitochondria and Bioblasts

69 **2. Coupling states and rates in mitochondrial preparations**

70 Mitochondrial preparations

71 *2.1. Respiratory control and coupling*

72 The steady-state

73 Specification of biochemical dose

74 Phosphorylation,  $P_{\gg}$ , and  $P_{\gg}/O_2$  ratio

75 Control and regulation

76 Respiratory control and response

77 Respiratory coupling control and ET-pathway control

78 Coupling

79 Uncoupling

80 *2.2. Coupling states and respiratory rates*

81 Respiratory capacities in coupling control states

82 LEAK, OXPHOS, ET, ROX

83 *2.3. Classical terminology for isolated mitochondria*

84 States 1–5

85 **3. What is a rate?** – Box 2: Metabolic flows and fluxes: vectorial, vectorial, and scalar

86 **4. Normalization of rate per sample**

87 *4.1. Flow: per object*

88 *4.2. Size-specific flux: per sample size*

89 *4.3. Marker-specific flux: per mitochondrial content*

90 **5. Normalization of rate per system**

91 *5.1. Flow: per chamber*

92 *5.2. Flux: per chamber volume*

93 **6. Conversion of units**

94 **7. Conclusions** – Box 3: Recommendations for studies with mitochondrial preparations

95 **References**

96

**Abstract** As the knowledge base and importance of mitochondrial physiology to human health expands, the necessity for harmonizing the terminology concerning mitochondrial respiratory states and rates has become increasingly apparent. The chemiosmotic theory establishes the mechanism of energy transformation and coupling in oxidative phosphorylation. The unifying concept of the protonmotive force provides the framework for developing a consistent theoretical foundation of mitochondrial physiology and bioenergetics. We follow IUPAC guidelines on terminology in physical chemistry, extended by considerations on open systems and thermodynamics of irreversible processes. The concept-driven constructive terminology incorporates the meaning of each quantity and aligns concepts and symbols to the nomenclature of classical bioenergetics. We endeavour to provide a balanced view on mitochondrial respiratory control and a critical discussion on reporting data of mitochondrial respiration in terms of metabolic flows and fluxes. Uniform standards for evaluation of respiratory states and rates will ultimately support the development of databases of mitochondrial respiratory function in species, tissues, and cells. Clarity of concept and consistency of nomenclature facilitate effective transdisciplinary communication, education, and ultimately further discovery.

*Keywords:* Mitochondrial respiratory control, coupling control, mitochondrial preparations, protonmotive force, uncoupling, oxidative phosphorylation, OXPHOS, efficiency, electron transfer, ET; proton leak, LEAK, residual oxygen consumption, ROX, State 2, State 3, State 4, normalization, flow, flux, O<sub>2</sub>

---

## Executive summary

In view of the broad implications for health care, mitochondrial researchers face an increasing responsibility to disseminate their fundamental knowledge and novel discoveries to a wide range of stakeholders and scientists beyond the group of specialists. This requires implementation of a commonly accepted terminology within the discipline and standardization in the translational context. Authors, reviewers, journal editors, and lecturers are challenged to collaborate with the aim to harmonize the nomenclature in the growing field of mitochondrial physiology and bioenergetics, from evolutionary biology and comparative physiology to mitochondrial medicine. In the present communication we focus on the following aspects of mitochondrial physiology:

1. Aerobic respiration depends on the coupling of phosphorylation ( $\text{ADP} \rightarrow \text{ATP}$ ) to O<sub>2</sub> flux in catabolic reactions. Coupling in oxidative phosphorylation is mediated by translocation of protons across the inner mitochondrial membrane through proton pumps generating or utilizing the protonmotive force, that is measured between the mitochondrial matrix and intermembrane compartment or outer mitochondrial space. Compartmental coupling distinguishes vectorial oxidative phosphorylation from glycolytic fermentation as the counterpart of cellular core energy metabolism (**Figure 1**). Cell respiration is distinguished from fermentation by: (1) Electron acceptors supplied by external respiration for the maintenance of redox balance, whereas fermentation is characterized by an internal electron acceptor produced in intermediary metabolism. In aerobic cell respiration, redox balance is maintained by O<sub>2</sub> as the electron acceptor. (2) Compartmental coupling in vectorial oxidative phosphorylation, in contrast to exclusively scalar substrate-level phosphorylation in fermentation.
2. To exclude fermentation and other cytosolic interactions from exerting an effect on the analysis of mitochondrial metabolism, the barrier function of the plasma membrane must be disrupted. Selective removal or permeabilization of the plasma membrane yields mitochondrial preparations—including isolated mitochondria, tissue and cellular preparations—with structural and functional integrity. Then extra-mitochondrial concentrations of fuel substrates, ADP, ATP, inorganic phosphate,

and cations including  $H^+$  can be controlled to determine mitochondrial function under a set of conditions defined as coupling control states. A concept-driven terminology of bioenergetics explicitly incorporates in its terms and symbols information on the nature of respiratory states that makes the technical terms readily recognized and easier to understand.


**Figure 1. Mitochondrial respiration is the oxidation of fuel substrates (electron donors) and reduction of  $O_2$  catalysed by the electron transfer system, ETS: (a) mitochondrial catabolic respiration; (b) total cellular  $O_2$  consumption; and (c) external respiration**

All chemical reactions,  $r$ , that consume  $O_2$  in the cells of an organism, contribute to cell respiration,  $J_{rO_2}$ . **1** Mitochondrial residual oxygen consumption,  $Rox$ . **2** Non-mitochondrial  $O_2$  consumption by catabolic reactions, particularly peroxisomal oxidases and microsomal cytochrome P450 systems. **3** Non-mitochondrial  $Rox$  by reactions unrelated to catabolism. **4** Aerobic microbial respiration. **5** Extracellular  $O_2$  consumption. Bars are not at a quantitative scale.

**a Mitochondrial catabolic respiration**,  $J_{kO_2}$ , is the  $O_2$  consumption by the mitochondrial ETS excluding  $Rox$ .

**b Cell respiration**,  $J_{rO_2}$ , takes into account internal  $O_2$ -consuming reactions,  $r$ , including catabolic respiration and  $Rox$ . Catabolic cell respiration is the  $O_2$  consumption associated with catabolic pathways in the cell, including mitochondrial catabolism in addition to peroxisomal and microsomal oxidation reactions (**2**).

**c External respiration** balances internal respiration at steady-state, including aerobic respiration by the microbiome (**4**) and extracellular  $O_2$  consumption (**5**).  $O_2$  is transported from the environment across the respiratory cascade, *i.e.*, circulation between tissues and diffusion across cell membranes, to the intracellular compartment. The respiratory quotient,  $RQ$ , is the molar  $CO_2/O_2$  exchange ratio; when combined with the respiratory nitrogen quotient,  $N/O_2$  (mol N given off per mol  $O_2$  consumed), the  $RQ$  reflects the proportion of carbohydrate, lipid and protein utilized in cell respiration during aerobically balanced steady-states. Bicarbonate and  $CO_2$  are transported in reverse to the extracellular milieu and the organismic environment. Hemoglobin provides the molecular paradigm for the combination of  $O_2$  and  $CO_2$  exchange, as do lungs and gills on the morphological level.



- 199 3. Mitochondrial coupling states are defined according to the control of respiratory oxygen  
 200 flux by the protonmotive force. Capacities of oxidative phosphorylation and  
 201 electron transfer are measured at kinetically saturating concentrations of fuel  
 202 substrates, ADP and inorganic phosphate, and O<sub>2</sub>, or at optimal uncoupler  
 203 concentrations, respectively, in the absence of Complex IV inhibitors such as NO,  
 204 CO, or H<sub>2</sub>S. Respiratory capacity is a measure of the upper bound of the rate of  
 205 respiration, depends on the substrate type undergoing oxidation, and provides  
 206 reference values for the diagnosis of health and disease, and for evaluation of the  
 207 effects of Evolutionary background, Age, Gender and sex, Lifestyle and  
 208 Environment.
- 209 4. Incomplete tightness of coupling, *i.e.*, some degree of uncoupling relative to the  
 210 substrate-dependent coupling stoichiometry, is a characteristic of energy-  
 211 transformations across membranes. Uncoupling is caused by a variety of  
 212 physiological, pathological, toxicological, pharmacological and environmental  
 213 conditions that exert an influence not only on the proton leak and cation cycling,  
 214 but also on proton slip within the proton pumps and the structural integrity of the  
 215 mitochondria. A more loosely coupled state is induced by stimulation of  
 216 mitochondrial superoxide formation and the bypass of proton pumps. In addition,  
 217 uncoupling by application of protonophores represents an experimental  
 218 intervention for the transition from a well-coupled to the noncoupled state of  
 219 mitochondrial respiration.
- 220 5. Respiratory oxygen consumption rates have to be carefully normalized to enable meta-  
 221 analytic studies beyond the question of a particular experiment. Therefore, all raw  
 222 data should be published in a supplemental table or open access data repository.  
 223 Sample-specific normalization of rates for: (1) the number of objects (cells,  
 224 organisms); (2) the volume or mass of the experimental sample; and (3) the  
 225 concentration of mitochondrial markers in the experimental chamber is  
 226 distinguished from system-specific normalization for the volume of the chamber  
 227 (the measuring system).
- 228 6. The consistent use of terms and symbols will facilitate transdisciplinary communication  
 229 and support further developments of a database on bioenergetics and mitochondrial  
 230 physiology. The present considerations are focused on studies with mitochondrial  
 231 preparations. These will be extended in a series of reports on pathway control of  
 232 mitochondrial respiration, respiratory states in intact cells, and harmonization of  
 233 experimental procedures.

---

### 237 **Box 1: In brief – Mitochondria and Bioblasts**

238 *‘For the physiologist, mitochondria afforded the first opportunity for an*  
 239 *experimental approach to structure-function relationships, in particular those*  
 240 *involved in active transport, vectorial metabolism, and metabolic control*  
 241 *mechanisms on a subcellular level’ (Ernster and Schatz 1981).*

242 **Mitochondria** are the oxygen-consuming electrochemical generators evolved from  
 243 endosymbiotic bacteria (Margulis 1970; Lane 2005). They were described by Richard Altmann  
 244 (1894) as ‘bioblasts’, which include not only the mitochondria as presently defined, but also  
 245 symbiotic and free-living bacteria. The word ‘mitochondria’ (Greek mitos: thread; chondros:  
 246 granule) was introduced by Carl Benda (1898).

247 Mitochondria form dynamic networks within eukaryotic cells and are morphologically  
 248 enclosed by a double membrane. The mitochondrial inner membrane (mtIM) shows dynamic  
 249 tubular to disk-shaped cristae that separate the mitochondrial matrix, *i.e.*, the negatively charged  
 250 internal mitochondrial compartment, from the intermembrane space; the latter being enclosed

251 by the mitochondrial outer membrane (mtOM) and positively charged with respect to the  
252 matrix. The mtIM contains the non-bilayer phospholipid cardiolipin, which is not present in  
253 any other eukaryotic cellular membrane. Cardiolipin stabilizes and promotes the formation of  
254 respiratory supercomplexes (SC I<sub>n</sub>III<sub>n</sub>IV<sub>n</sub>), which are supramolecular assemblies based upon  
255 specific, though dynamic interactions between individual respiratory complexes (Greggio *et al.*  
256 2017; Lenaz *et al.* 2017). Membrane fluidity exerts an influence on functional properties of  
257 proteins incorporated in the membranes (Waczulikova *et al.* 2007). In addition to mitochondrial  
258 movement along microtubules, mitochondrial morphology can change in response to energy  
259 requirements of the cell via processes known as fusion and fission, through which mitochondria  
260 communicate within a network (Chan 2006). Intracellular stress factors may cause shrinking or  
261 swelling of the mitochondrial matrix, that can ultimately result in permeability transition.

262 Mitochondria are the structural and functional elementary components of cell respiration.  
263 Mitochondrial respiration is the reduction of molecular oxygen by electron transfer coupled to  
264 electrochemical proton translocation across the mtIM. In the process of oxidative  
265 phosphorylation (OXPHOS), the catabolic reaction of oxygen consumption is  
266 electrochemically coupled to the transformation of energy in the form of adenosine triphosphate  
267 (ATP; Mitchell 1961, 2011). Mitochondria are the powerhouses of the cell which contain the  
268 machinery of the OXPHOS-pathways, including transmembrane respiratory complexes (proton  
269 pumps with FMN, Fe-S and cytochrome *b*, *c*, *aa3* redox systems); alternative dehydrogenases  
270 and oxidases; the coenzyme ubiquinone (Q); F-ATPase or ATP synthase; the enzymes of the  
271 tricarboxylic acid cycle, fatty acid and amino acid oxidation; transporters of ions, metabolites  
272 and co-factors; iron/sulphur cluster synthesis; and mitochondrial kinases related to energy  
273 transfer pathways. The mitochondrial proteome comprises over 1,200 proteins (Calvo *et al.*  
274 2015; 2017), mostly encoded by nuclear DNA (nDNA), with a variety of functions, many of  
275 which are relatively well known (*e.g.*, proteins regulating mitochondrial biogenesis or  
276 apoptosis), while others are still under investigation, or need to be identified (*e.g.*, alanine  
277 transporter). Only recently has it been possible to use the mammalian mitochondrial proteome  
278 to discover and characterize the genetic basis of mitochondrial diseases (Williams *et al.* 2016;  
279 Palmfeldt and Bross 2017).

280 Mitochondria can traverse cell boundaries in a process known as horizontal mitochondrial  
281 transfer (Torralba *et al.* 2016). There is a constant crosstalk between mitochondria and the other  
282 cellular components. The crosstalk between mitochondria and endoplasmic reticulum is  
283 involved in the regulation of calcium homeostasis, cell division, autophagy, differentiation, and  
284 anti-viral signaling (Murley and Nunnari 2016). Mitochondria contribute to the formation of  
285 peroxisomes, which are hybrids of mitochondrial and ER-derived precursors (Sugiura *et al.*  
286 2017). Cellular mitochondrial homeostasis (mitostasis) is maintained through regulation at  
287 transcriptional, post-translational and epigenetic levels. Cell signalling modules contribute to  
288 homeostatic regulation throughout the cell cycle or even cell death by activating proteostatic  
289 modules (*e.g.*, the ubiquitin-proteasome and autophagy-lysosome/vacuole pathways; specific  
290 proteases like LON) and genome stability modules in response to varying energy demands and  
291 stress cues (Quiros *et al.* 2016). Acetylation is a post-translational modification capable of  
292 influencing the bioenergetic response, with clinically significant implications for health and  
293 disease (Carrico *et al.* 2018).

294 Mitochondria typically maintain several copies of their own circular genome known as  
295 mitochondrial DNA (mtDNA; hundred to thousands per cell; Cummins 1998), which is  
296 maternally inherited in humans. Biparental mitochondrial inheritance is documented in  
297 mammals, birds, fish, reptiles and invertebrate groups, and is even the norm in some bivalve  
298 taxonomic groups (Breton *et al.* 2007; White *et al.* 2008). The mitochondrial genome of the  
299 angiosperm *Amborella* contains a record of six mitochondrial genome equivalents acquired by  
300 horizontal transfer of entire genomes, two from angiosperms, three from algae and one from  
301 mosses (Rice *et al.* 2016). However, some organisms such as *Cryptosporidium* species have

302 morphologically and functionally reduced mitochondria without DNA (Liu *et al.* 2016). In  
303 vertebrates but not all invertebrates, mtDNA is compact (16.5 kB in humans) and encodes 13  
304 protein subunits of the transmembrane respiratory Complexes CI, CIII, CIV and F-ATPase, 22  
305 tRNAs, and two RNAs. Additional gene content has been suggested to include microRNAs,  
306 piRNA, smithRNAs, repeat associated RNA, and even additional proteins (Duarte *et al.* 2014;  
307 Lee *et al.* 2015; Cobb *et al.* 2016). The mitochondrial genome requires nuclear-encoded  
308 mitochondrially targeted proteins, *e.g.*, TFAM, for its maintenance and expression (Rackham  
309 *et al.* 2012). Both genomes encode peptides of the membrane spanning redox pumps (CI, CIII  
310 and CIV) and F-ATPase, leading to strong constraints in the coevolution of both genomes (Blier  
311 *et al.* 2001).

312 Mitochondrial dysfunction is associated with a wide variety of genetic and degenerative  
313 diseases. Robust mitochondrial function is supported by physical exercise and caloric balance,  
314 and is central for sustained metabolic health throughout life. Therefore, a more consistent  
315 presentation of mitochondrial physiology will improve our understanding of the etiology of  
316 disease, the diagnostic repertoire of mitochondrial medicine, with a focus on protective  
317 medicine, lifestyle and healthy aging.

318 Abbreviation: mt, as generally used in mtDNA. Mitochondrion is singular and  
319 mitochondria is plural.

320

321

## 322 1. Introduction

323

324 Mitochondria are the powerhouses of the cell with numerous physiological, molecular,  
325 and genetic functions (**Box 1**). Every study of mitochondrial health and disease is faced with  
326 Evolution, Age, Gender and sex, Lifestyle, and Environment (MitoEAGLE) as essential  
327 background conditions intrinsic to the individual person or cohort, species, tissue and to some  
328 extent even cell line. As a large and coordinated group of laboratories and researchers, the  
329 mission of the global MitoEAGLE Network is to generate the necessary scale, type, and quality  
330 of consistent data sets and conditions to address this intrinsic complexity. Harmonization of  
331 experimental protocols and implementation of a quality control and data management system  
332 are required to interrelate results gathered across a spectrum of studies and to generate a  
333 rigorously monitored database focused on mitochondrial respiratory function. In this way,  
334 researchers from a variety of disciplines can compare their findings using clearly defined and  
335 accepted international standards.

336 Reliability and comparability of quantitative results depend on the accuracy of  
337 measurements under strictly-defined conditions. A conceptual framework is required to warrant  
338 meaningful interpretation and comparability of experimental outcomes carried out by research  
339 groups at different institutes. With an emphasis on quality of research, collected data can be  
340 useful far beyond the specific question of a particular experiment. Standardization and  
341 homogenization of terminology, methodology, and data sets could lead to the development of  
342 open-access databases such as those that have been developed for National Institutes of Health  
343 sponsored research in genetics, proteomics, and metabolomics. Enabling meta-analytic studies  
344 is the most economic way of providing robust answers to biological questions (Cooper *et al.*  
345 2009). Vague or ambiguous jargon can lead to confusion and may relegate valuable signals to  
346 wasteful noise. For this reason, measured values must be expressed in standard units for each  
347 parameter used to define mitochondrial respiratory function. Harmonization of nomenclature  
348 and definition of technical terms are essential to improve the awareness of the intricate meaning  
349 of current and past scientific vocabulary, for documentation and integration into databases in  
350 general, and quantitative modelling in particular (Beard 2005). The focus on coupling states  
351 and fluxes through metabolic pathways of aerobic energy transformation in mitochondrial  
352 preparations is a first step in the attempt to generate a conceptually-oriented nomenclature in

353 bioenergetics and mitochondrial physiology. Coupling states of intact cells, the protonmotive  
354 force, and respiratory control by fuel substrates and specific inhibitors of respiratory enzymes  
355 will be reviewed in subsequent communications, prepared In the frame of COST Action  
356 MitoEAGLE open to global bottom-up input.

357  
358

## 359 **2. Coupling states and rates in mitochondrial preparations**

360 *‘Every professional group develops its own technical jargon for talking about matters of*  
361 *critical concern ... People who know a word can share that idea with other members of*  
362 *their group, and a shared vocabulary is part of the glue that holds people together and*  
363 *allows them to create a shared culture’ (Miller 1991).*

364

365 **Mitochondrial preparations** are defined as either isolated mitochondria, or tissue and  
366 cellular preparations in which the barrier function of the plasma membrane is disrupted. Since  
367 this entails the loss of cell viability, mitochondrial preparations are not studied *in vivo*. In  
368 contrast to isolated mitochondria and tissue homogenate preparations, mitochondria in  
369 permeabilized tissues and cells are *in situ* relative to the plasma membrane. The plasma  
370 membrane separates the intracellular compartment including the cytosol, nucleus, and  
371 organelles from the extracellular environment. The plasma membrane consists of a lipid bilayer  
372 with embedded proteins and attached organic molecules that collectively control the selective  
373 permeability of ions, organic molecules, and particles across the cell boundary. The intact  
374 plasma membrane prevents the passage of many water-soluble mitochondrial substrates and  
375 inorganic ions—such as succinate, adenosine diphosphate (ADP) and inorganic phosphate (P<sub>i</sub>),  
376 that must be controlled at kinetically-saturating concentrations for the analysis of respiratory  
377 capacities. Despite the activity of solute carriers, *e.g.*, SLC13A3 and SLC20A2, that transport  
378 these metabolites across the plasma membrane of various cell types, this limits the scope of  
379 investigations into mitochondrial respiratory function in intact cells (**Figure 2A**).

380 The cholesterol content of the plasma membrane is high compared to mitochondrial  
381 membranes (Korn 1969). Therefore, mild detergents—such as digitonin and saponin—can be  
382 applied to selectively permeabilize the plasma membrane by interaction with cholesterol and  
383 allow free exchange of organic molecules and inorganic ions between the cytosol and the  
384 immediate cell environment, while maintaining the integrity and localization of organelles,  
385 cytoskeleton, and the nucleus. Application of optimum concentrations of permeabilization  
386 agents (mild detergents or toxins) leads to washout of cytosolic marker enzymes—such as  
387 lactate dehydrogenase—and results in the complete loss of cell viability, tested by nuclear  
388 staining using membrane-impermeable dyes, while mitochondrial function remains intact,  
389 tested by cytochrome *c* addition, for example. Respiration of isolated mitochondria remains  
390 unaltered after the addition of low concentrations of digitonin or saponin, although care should  
391 be taken when isolating mitochondria from cancer cells since they have significantly higher  
392 contents of cholesterol in both membranes (Baggetto and Testa-Perussini, 1990). In addition to  
393 mechanical cell disruption during homogenization of tissue, permeabilization agents may be  
394 applied to ensure permeabilization of all cells in tissue homogenates. Suspensions of cells  
395 permeabilized in the respiration chamber and crude tissue homogenates contain all components  
396 of the cell at highly dilute concentrations. All mitochondria are retained in chemically-  
397 permeabilized mitochondrial preparations and crude tissue homogenates. In the preparation of  
398 isolated mitochondria, however, the mitochondria are separated from other cell fractions and  
399 purified by differential centrifugation, entailing the loss of a fraction of the total mitochondrial  
400 content. Typical mitochondrial recovery ranges from 30% to 80%. Using Percoll or sucrose  
401 density gradients to maximize the purity of isolated mitochondria may compromise the  
402 mitochondrial yield or structural and functional integrity. Therefore, protocols to isolate  
403 mitochondria need to be optimized according to each study. The term mitochondrial preparation



404 does neither include further fractionation of mitochondrial components, nor submitochondrial  
 405 particles.

406

### 407 2.1. Respiratory control and coupling

408

409 Respiratory coupling control states are established in studies of mitochondrial  
 410 preparations to obtain reference values for various output variables (**Table 1**). Physiological  
 411 conditions *in vivo* deviate from these experimentally obtained states. Since kinetically-  
 412 saturating concentrations, *e.g.*, of ADP or oxygen (O<sub>2</sub>; dioxygen), may not apply to  
 413 physiological intracellular conditions, relevant information is obtained in studies of kinetic  
 414 responses to variations in [ADP] or [O<sub>2</sub>] in the range between kinetically-saturating  
 415 concentrations and anoxia (Gnaiger 2001).


416 **The steady-state:** Mitochondria represent a thermodynamically open system in non-  
 417 equilibrium states of biochemical energy transformation. State variables (protonmotive force;  
 418 redox states) and metabolic *rates* (fluxes) are measured in defined mitochondrial respiratory  
 419 *states*. Steady-states can be obtained only in open systems, in which changes by *internal*  
 420 transformations, *e.g.*, O<sub>2</sub> consumption, are instantaneously compensated for by *external* fluxes,  
 421 *e.g.*, O<sub>2</sub> supply, preventing a change of O<sub>2</sub> concentration in the system (Gnaiger 1993b).  
 422 Mitochondrial respiratory states monitored in closed systems satisfy the criteria of pseudo-  
 423 steady states for limited periods of time, when changes in the system (concentrations of O<sub>2</sub>, fuel  
 424 substrates, ADP, P<sub>i</sub>, H<sup>+</sup>) do not exert significant effects on metabolic fluxes (respiration,  
 425 phosphorylation). Such pseudo-steady states require respiratory media with sufficient buffering  
 426 capacity and substrates maintained at kinetically-saturating concentrations, and thus depend on  
 427 the kinetics of the processes under investigation.

428 **Specification of biochemical dose:** Substrates, uncouplers, inhibitors, and other  
 429 chemical reagents are titrated to dissect mitochondrial function. Nominal concentrations of  
 430 these substances are usually reported as initial amount of substance concentration [mol·L<sup>-1</sup>] in  
 431 the incubation medium. When aiming at the measurement of kinetically saturated processes—  
 432 such as OXPHOS-capacities, the concentrations for substrates can be chosen according to the  
 433 apparent equilibrium constant,  $K_m'$ . In the case of hyperbolic kinetics, only 80% of maximum  
 434 respiratory capacity is obtained at a substrate concentration of four times the  $K_m'$ , whereas  
 435 substrate concentrations of 5, 9, 19 and 49 times the  $K_m'$  are theoretically required for reaching  
 436 83%, 90%, 95% or 98% of the maximal rate (Gnaiger 2001). Other reagents are chosen to  
 437 inhibit or alter some processes. The amount of these chemicals in an experimental incubation  
 438 is selected to maximize effect, avoiding unacceptable off-target consequences that would  
 439 adversely affect the data being sought. Specifying the amount of substance in an incubation as  
 440 nominal concentration in the aqueous incubation medium can be ambiguous (Doskey *et al.*  
 441 2015), particularly for lipophilic substances (oligomycin, uncouplers, permeabilization agents)  
 442 or cations (TPP<sup>+</sup>; fluorescent dyes such as safranin, TMRM; Chowdhury *et al.* 2015), which  
 443 accumulate in biological membranes or in the mitochondrial matrix. For example, a dose of  
 444 digitonin of 8 fmol·cell<sup>-1</sup> (10 pg·cell<sup>-1</sup>; 10 µg·10<sup>-6</sup> cells) is optimal for permeabilization of  
 445 endothelial cells, and the concentration in the incubation medium has to be adjusted according  
 446 to the cell density applied (Doerrier *et al.* 2018).

447 Generally, dose/exposure can be specified per unit of biological sample, *i.e.*, (nominal  
 448 moles of xenobiotic)/(number of cells) [mol·cell<sup>-1</sup>] or, as appropriate, per mass of biological  
 449 sample [mol·kg<sup>-1</sup>]. This approach to specification of dose/exposure provides a scalable  
 450 parameter that can be used to design experiments, help interpret a wide variety of experimental  
 451 results, and provide absolute information that allows researchers worldwide to make the most  
 452 use of published data (Doskey *et al.* 2015).

453 **Phosphorylation, P<sub>»</sub>, and P<sub>»</sub>/O<sub>2</sub> ratio:** *Phosphorylation* in the context of OXPHOS is  
 454 defined as phosphorylation of ADP by P<sub>i</sub> to form ATP. On the other hand, the term

455 phosphorylation is used generally in many contexts, *e.g.*, protein phosphorylation. This justifies  
 456 consideration of a symbol more discriminating and specific than P as used in the P/O ratio  
 457 (phosphate to atomic oxygen ratio), where P indicates phosphorylation of ADP to ATP or GDP  
 458 to GTP (**Figure 2**). We propose the symbol P» for the endergonic (uphill) direction of  
 459 phosphorylation ADP→ATP, and likewise the symbol P« for the corresponding exergonic  
 460 (downhill) hydrolysis ATP→ADP (**Figure 3**). P» refers mainly to electrontransfer  
 461 phosphorylation but may also involve substrate-level phosphorylation as part of the  
 462 tricarboxylic acid (TCA) cycle (succinyl-CoA ligase; phosphoglycerate kinase) and  
 463 phosphorylation of ADP catalyzed by pyruvate kinase, and of GDP phosphorylated by  
 464 phosphoenolpyruvate carboxykinase. Transphosphorylation is performed by adenylate kinase,  
 465 creatine kinase (mtCK), hexokinase and nucleoside diphosphate kinase. In isolated mammalian  
 466 mitochondria, ATP production catalyzed by adenylate kinase (2 ADP ↔ ATP + AMP) proceeds  
 467 without fuel substrates in the presence of ADP (Komlódi and Tretter 2017). Kinase cycles are  
 468 involved in intracellular energy transfer and signal transduction for regulation of energy flux.  
 469



470

471

## Figure 2. Cell respiration and oxidative phosphorylation (OXPHOS)

472 Mitochondrial respiration is the oxidation of fuel substrates (electron donors) with electron  
 473 transfer to  $O_2$  as the electron acceptor. For explanation of symbols see also **Figure 1**.

474 **(A)** Respiration of intact cells: Extra-mitochondrial catabolism of macrofuels or uptake of small  
 475 molecules by the cell provides the *mitochondrial* fuel substrates. Many fuel substrates are  
 476 catabolized to acetyl-CoA or to glutamate, and further electron transfer reduces nicotinamide  
 477 adenine dinucleotide to NADH or flavin adenine dinucleotide to  $FADH_2$ . In respiration,  
 478 electron transfer is coupled to the phosphorylation of ADP to ATP, with energy transformation  
 479 mediated by the protonmotive force,  $\Delta p$ . Anabolic reactions are linked to catabolism, both by  
 480 ATP as the intermediary energy currency and by small organic precursor molecules as building  
 481 blocks for biosynthesis (not shown). Glycolysis involves substrate-level phosphorylation of  
 482 ADP to ATP in fermentation without utilization of  $O_2$ . In contrast, extra-mitochondrial  
 483 oxidation of fatty acids and amino acids proceeds partially in peroxisomes without coupling to  
 484 ATP production: acyl-CoA oxidase catalyzes the oxidation of  $FADH_2$  with electron transfer to  
 485  $O_2$ ; amino acid oxidases oxidize flavin mononucleotide  $FMNH_2$  or  $FADH_2$ . Coenzyme Q, Q,  
 486 and the cytochromes *b*, *c*, and *aa<sub>3</sub>* are redox systems of the mitochondrial inner membrane,  
 487 mtIM. Dashed arrows indicate the connection between the redox proton pumps (respiratory  
 488 Complexes CI, CIII and CIV) and the transmembrane  $\Delta p$ . Mitochondrial outer membrane,  
 489 mtOM; glycerol-3-phosphate, Gp; tricarboxylic acid cycle, TCA cycle.

490 **(B)** Respiration in mitochondrial preparations: The mitochondrial electron transfer system  
 491 (ETS) is (1) fuelled by diffusion and transport of substrates across the mitochondrial outer and  
 492 inner membrane, and in addition consists of the (2) matrix-ETS, and (3) membrane-ETS.

493 Upstream sections of ET-pathways converge at the N-junction. NADH mainly generated in the  
 494 TCA cycle is oxidized by CI and electron entry into the Q-junction. Similarly, succinate is  
 495 formed in the TCA cycle and oxidized by CII to fumarate. CII is part of both the TCA cycle  
 496 and the ETS, and reduces FAD to FADH<sub>2</sub> with further reduction of ubiquinone to ubiquinol  
 497 downstream of the TCA cycle in the Q-junction. Thus FADH<sub>2</sub> is not a substrate but is the  
 498 product of CII, in contrast to erroneous metabolic maps shown in many textbooks and  
 499 publications. Unspecified arrows converging at the Q-junction indicate additional ET-sections  
 500 with electron entry into Q through electron transferring flavoprotein, glycerophosphate  
 501 dehydrogenase, dihydro-orotate dehydrogenase, proline dehydrogenase, choline  
 502 dehydrogenase, and sulfide-ubiquinone oxidoreductase. The dotted arrow indicates the  
 503 branched pathway of oxygen consumption by alternative quinol oxidase (AOX). ET-pathways  
 504 are coupled to the phosphorylation-pathway. The H<sup>+</sup><sub>pos</sub>/O<sub>2</sub> ratio is the outward proton flux from  
 505 the matrix space to the positively (pos) charged vesicular compartment, divided by catabolic  
 506 O<sub>2</sub> flux in the NADH-pathway. The H<sup>+</sup><sub>neg</sub>/P<sub>»</sub> ratio is the inward proton flux from the inter-  
 507 membrane space to the negatively (neg) charged matrix space, divided by the flux of  
 508 phosphorylation of ADP to ATP. These stoichiometries are not fixed due to ion leaks and proton  
 509 slip.

510 (C) Chemiosmotic phosphorylation-pathway catalyzed by the proton pump F<sub>1</sub>F<sub>0</sub>-ATPase (F-  
 511 ATPase, ATP synthase), adenine nucleotide translocase, and inorganic phosphate transporter.  
 512 The H<sup>+</sup><sub>neg</sub>/P<sub>»</sub> stoichiometry is the sum of the coupling stoichiometry in the F-ATPase reaction  
 513 (-2.7 H<sup>+</sup><sub>pos</sub> from the positive intermembrane space, 2.7 H<sup>+</sup><sub>neg</sub> to the matrix, *i.e.*, the negative  
 514 compartment) and the proton balance in the translocation of ADP<sup>3-</sup>, ATP<sup>4-</sup> and P<sub>i</sub><sup>2-</sup>. Modified  
 515 from (B) Lemieux *et al.* (2017) and (C) Gnaiger (2014).

516  
 517 The P<sub>»</sub>/O<sub>2</sub> ratio (P<sub>»</sub>/4 e<sup>-</sup>) is two times the ‘P/O’ ratio (P<sub>»</sub>/2 e<sup>-</sup>) of classical bioenergetics.  
 518 P<sub>»</sub>/O<sub>2</sub> is a generalized symbol, not specific for determination of P<sub>i</sub> consumption (P<sub>i</sub>/O<sub>2</sub> flux  
 519 ratio), ADP depletion (ADP/O<sub>2</sub> flux ratio), or ATP production (ATP/O<sub>2</sub> flux ratio). The  
 520 mechanistic P<sub>»</sub>/O<sub>2</sub> ratio—or P<sub>»</sub>/O<sub>2</sub> stoichiometry—is calculated from the proton-to-O<sub>2</sub> and  
 521 proton-to-phosphorylation coupling stoichiometries (**Figure 2B**):  
 522

$$523 \quad P_{\gg}/O_2 = \frac{H_{\text{pos}}^+/O_2}{H_{\text{neg}}^+/P_{\gg}} \quad (1)$$

524  
 525 The H<sup>+</sup><sub>pos</sub>/O<sub>2</sub> *coupling stoichiometry* (referring to the full 4 electron reduction of O<sub>2</sub>) depends  
 526 on the relative involvement of the three coupling sites (respiratory Complexes I, III and IV; CI,  
 527 CIII and CIV) in the catabolic ET-pathway from reduced fuel substrates (electron donors) to  
 528 the reduction of O<sub>2</sub> (electron acceptor). This varies with: (1) a bypass of CI by single or multiple  
 529 electron input into the Q-junction; and (2) a bypass of CIV by involvement of alternative  
 530 oxidases, AOX, which are not expressed in mammalian mitochondria.

531 H<sup>+</sup><sub>pos</sub>/O<sub>2</sub> is 12 in the ET-pathways involving CIII and CIV as proton pumps, increasing to  
 532 20 for the NADH-pathway through CI (**Figure 2B**), but a general consensus on H<sup>+</sup><sub>pos</sub>/O<sub>2</sub>  
 533 stoichiometries remains to be reached (Hinkle 2005; Wikström and Hummer 2012; Sazanov  
 534 2015). The H<sup>+</sup><sub>neg</sub>/P<sub>»</sub> coupling stoichiometry (3.7; **Figure 2B**) is the sum of 2.7 H<sup>+</sup><sub>neg</sub> required  
 535 by the F-ATPase of vertebrate and most invertebrate species (Watt *et al.* 2010) and the proton  
 536 balance in the translocation of ADP, ATP and P<sub>i</sub> (**Figure 2C**). Taken together, the mechanistic  
 537 P<sub>»</sub>/O<sub>2</sub> ratio is calculated at 5.4 and 3.3 for NADH- and succinate-linked respiration,  
 538 respectively (Eq. 1). The corresponding classical P<sub>»</sub>/O ratios (referring to the 2 electron  
 539 reduction of 0.5 O<sub>2</sub>) are 2.7 and 1.6 (Watt *et al.* 2010), in agreement with the measured P<sub>»</sub>/O  
 540 ratio for succinate of 1.58 ± 0.02 (Gnaiger *et al.* 2000).

541 The effective P<sub>»</sub>/O<sub>2</sub> flux ratio ( $\dot{Y}_{P_{\gg}/O_2} = J_{P_{\gg}}/J_{kO_2}$ ; **Figure 3**) is diminished relative to the  
 542 mechanistic P<sub>»</sub>/O<sub>2</sub> ratio by intrinsic and extrinsic uncoupling *versus* dyscoupling (**Figure 4**).  
 543 Such generalized uncoupling is different from switching to mitochondrial pathways that involve


544 fewer than three proton pumps ('coupling sites': Complexes CI, CIII and CIV), bypassing CI  
 545 through multiple electron entries into the Q-junction, or CIII and CIV through AOX (**Figure**  
 546 **2B**). Reprogramming of mitochondrial pathways leading to different types of substrates being  
 547 oxidized may be considered as a switch of gears (changing the stoichiometry by altering the  
 548 substrate that is oxidized) rather than uncoupling (loosening the tightness of coupling relative  
 549 to a fixed stoichiometry). In addition,  $Y_{P\gg O_2}$  depends on several experimental conditions of flux  
 550 control, increasing as a hyperbolic function of [ADP] to a maximum value (Gnaiger 2001).

551 **Control and regulation:** The terms metabolic *control* and *regulation* are frequently used  
 552 synonymously, but are distinguished in metabolic control analysis: 'We could understand the  
 553 regulation as the mechanism that occurs when a system maintains some variable constant over  
 554 time, in spite of fluctuations in external conditions (homeostasis of the internal state). On the  
 555 other hand, metabolic control is the power to change the state of the metabolism in response to  
 556 an external signal' (Fell 1997). Respiratory control may be induced by experimental control  
 557 signals that *exert* an influence on: (1) ATP demand and ADP phosphorylation-rate; (2) fuel  
 558 substrate composition, pathway competition; (3) available amounts of substrates and O<sub>2</sub>, *e.g.*,  
 559 starvation and hypoxia; (4) the protonmotive force, redox states, flux–force relationships,  
 560 coupling and efficiency; (5) Ca<sup>2+</sup> and other ions including H<sup>+</sup>; (6) inhibitors, *e.g.*, nitric oxide  
 561 or intermediary metabolites such as oxaloacetate; (7) signalling pathways and regulatory  
 562 proteins, *e.g.*, insulin resistance, transcription factor hypoxia inducible factor 1. *Mechanisms* of  
 563 respiratory control and regulation include adjustments of: (1) enzyme activities by allosteric  
 564 mechanisms and phosphorylation; (2) enzyme content, concentrations of cofactors and  
 565 conserved moieties—such as adenylates, nicotinamide adenine dinucleotide [NAD<sup>+</sup>/NADH],  
 566 coenzyme Q, cytochrome *c*; (3) metabolic channeling by supercomplexes; and (4)  
 567 mitochondrial density (enzyme concentrations and membrane area) and morphology (cristae  
 568 folding, fission and fusion). Mitochondria are targeted directly by hormones, *e.g.*, progesterone  
 569 and glucacorticoids, which affect their energy metabolism (Lee *et al.* 2013; Gerö and Szabo  
 570 2016; Price and Dai 2016; Moreno *et al.* 2017). Evolutionary or acquired differences in the  
 571 genetic and epigenetic basis of mitochondrial function (or dysfunction) between individuals;  
 572 age; gender, biological sex, and hormone concentrations; life style including exercise and  
 573 nutrition; and environmental issues including thermal, atmospheric, toxic and pharmacological  
 574 factors, exert an influence on all control mechanisms listed above. For reviews, see Brown  
 575 1992; Gnaiger 1993a, 2009; 2014; Paradies *et al.* 2014; Morrow *et al.* 2017.

576 **Respiratory control and response:** Lack of control by a metabolic pathway, *e.g.*,  
 577 phosphorylation-pathway, means that there will be no response to a variable activating it, *e.g.*,  
 578 [ADP]. The reverse, however, is not true as the absence of a response to [ADP] does not exclude  
 579 the phosphorylation-pathway from having some degree of control. The degree of control of a  
 580 component of the OXPHOS-pathway on an output variable—such as O<sub>2</sub> flux, will in general  
 581 be different from the degree of control on other outputs—such as phosphorylation-flux or  
 582 proton leak flux. Therefore, it is necessary to be specific as to which input and output are under  
 583 consideration (Fell 1997).

584 **Respiratory coupling control and ET-pathway control:** Respiratory control refers to  
 585 the ability of mitochondria to adjust O<sub>2</sub> flux in response to external control signals by engaging  
 586 various mechanisms of control and regulation. Respiratory control is monitored in a  
 587 mitochondrial preparation under conditions defined as respiratory states, preferentially under  
 588 near-physiological conditions of O<sub>2</sub> concentration, pH, temperature and medium ionic  
 589 composition, to generate data of higher biological relevance. When phosphorylation of ADP to  
 590 ATP is stimulated or depressed, an increase or decrease is observed in electron transfer  
 591 measured as O<sub>2</sub> flux in respiratory coupling states of intact mitochondria ('controlled states' in  
 592 the classical terminology of bioenergetics). Alternatively, coupling of electron transfer with  
 593 phosphorylation is disengaged by uncouplers. These protonophores are weak lipid-soluble acids  
 594 which disrupt the barrier function of the mtIM and thus short circuit the protonmotive system,

595 functioning like a clutch in a mechanical system. The corresponding coupling control state is  
 596 characterized by a high  $O_2$  flux without control by  $P_{\gg}$  (noncoupled or ‘uncontrolled state’).  
 597  
 598



599 **Figure 3. Coupling in oxidative phosphorylation (OXPHOS)**  
 600  $2[H]$  indicates the reduced hydrogen equivalents of fuel substrates of the catabolic reaction  $k$   
 601 with oxygen.  $O_2$  flux,  $J_{kO_2}$ , through the catabolic ET-pathway, is coupled to flux through the  
 602 phosphorylation-pathway of ADP to ATP,  $J_{P_{\gg}}$ . The redox proton pumps of the ET-pathway  
 603 drive proton flux into the positive (pos) compartment,  $J_{mH^{+}pos}$ , generating the output  
 604 protonmotive force (motive, subscript  $m$ ). F-ATPase is coupled to inward proton current into  
 605 the negative (neg) compartment,  $J_{mH^{+}neg}$ , to phosphorylate ADP to ATP. The system is defined  
 606 by the boundaries (full black line) and is not a black box, but is analysed as a compartmental  
 607 system. The negative compartment (neg-compartment, enclosed by the dotted line) is the  
 608 matrix space, separated by the mtIM from the positive compartment (pos-compartment).  
 609 ADP+ $P_i$  and ATP are the substrate- and product-compartments (scalar ADP and ATP  
 610 compartments, D-comp. and T-comp.), respectively. At steady-state proton turnover,  $J_{\infty H^{+}}$ , and  
 611 ATP turnover,  $J_{\infty P}$ , maintain concentrations constant, when  $J_{mH^{+}\infty} = J_{mH^{+}pos} = J_{mH^{+}neg}$ , and  $J_{P_{\infty}} = J_{P_{\gg}} = J_{P_{\ll}}$ . Modified from Gnaiger (2014).  
 612

613

614 ET-pathway control states are obtained in mitochondrial preparations by depletion of  
 615 endogenous substrates and addition to the mitochondrial respiration medium of fuel substrates  
 616 (Figure 2;  $2[H]$  in Figure 3) and specific inhibitors, activating selected mitochondrial catabolic  
 617 pathways,  $k$ , of electron transfer from the oxidation of fuel substrates to reduction of  $O_2$  (Figure  
 618 2A). Coupling control states and pathway control states are complementary, since  
 619 mitochondrial preparations depend on an exogenous supply of pathway-specific fuel substrates  
 620 and oxygen (Gnaiger 2014).  
 621

622 **Coupling:** In mitochondrial electron transfer, vectorial transmembrane proton flux is  
 623 coupled through the redox proton pumps CI, CIII and CIV to the catabolic flux of scalar  
 624 reactions, collectively measured as  $O_2$  flux (Figure 3). Thus mitochondria are elementary  
 625 components of energy transformation. Energy is a conserved quantity and cannot be lost or  
 626 produced in any internal process (First Law of thermodynamics). Open and closed systems can  
 627 gain or lose energy only by external fluxes—by exchange with the environment. Therefore,  
 628 energy can neither be produced by mitochondria, nor is there any internal process without  
 629 energy conservation. Exergy or Gibbs energy (‘free energy’) is the part of energy that can  
 630 potentially be transformed into work under conditions of constant volume and pressure.  
 Coupling is the interaction of an exergonic process (spontaneous, negative exergy change) with


631 an endergonic process (positive exergy change) in energy transformations which conserve part  
 632 of the exergy that would be irreversibly lost or dissipated in an uncoupled process.

633 **Uncoupling:** Uncoupling of mitochondrial respiration is a general term comprising  
 634 diverse mechanisms:

- 635 1. Proton leak across the mtIM from the pos- to the neg-compartment ( $H^+$  leak-  
 636 uncoupled; **Figure 4**).
- 637 2. Cycling of other cations, strongly stimulated by permeability transition; comparable  
 638 to the use of protonophores, cation cycling is experimentally induced by valinomycin  
 639 in the presence of  $K^+$ ;
- 640 3. Decoupling by proton slip in the redox proton pumps when protons are effectively not  
 641 pumped (CI, CIII and CIV) or are not driving phosphorylation (F-ATPase);
- 642 4. Loss of vesicular (compartmental) integrity when electron transfer is uncoupled;
- 643 5. Electron leak in the loosely coupled univalent reduction of  $O_2$  to superoxide ( $O_2^{\bullet-}$ ;  
 644 superoxide anion radical).

645 Differences of terms—uncoupled vs. noncoupled—are easily overlooked, although they relate  
 646 to different meanings of uncoupling (**Figure 4** and **Table 2**).

647  
 648



649  
 650  
 651  
 652  
 653  
 654  
 655  
 656  
 657  
 658  
 659  
 660  
 661  
 662  
 663

#### Figure 4. Mechanisms of respiratory uncoupling

An intact mitochondrial inner membrane, mtIM, is required for vectorial, compartmental coupling. ‘Acoupled’ respiration is the consequence of structural disruption with catalytic activity of non-compartmental mitochondrial fragments. Inducibly uncoupled (activation of UCP1) and experimentally noncoupled respiration (titration of protonophores) stimulate respiration to maximum  $O_2$  flux.  $H^+$  leak-uncoupled, decoupled, and loosely coupled respiration are components of intrinsic uncoupling (**Table 2**). Pathological dysfunction may affect all types of uncoupling, including permeability transition, causing intrinsically dyscoupled respiration. Similarly, toxicological and environmental stress factors can cause extrinsically dyscoupled respiration. Reduced fuel substrates, red; oxidized products, ox.

664 2.2. Coupling states and respiratory rates

665

666 **Respiratory capacities in coupling control states:** To extend the classical nomenclature  
 667 on mitochondrial coupling states (Section 2.3) by a concept-driven terminology that explicitly  
 668 incorporates information on the meaning of respiratory states, the terminology must be general  
 669 and not restricted to any particular experimental protocol or mitochondrial preparation (Gnaiger  
 670 2009). Concept-driven nomenclature aims at mapping the *meaning and concept behind the*  
 671 *words and acronyms onto the forms of words and acronyms* (Miller 1991). The focus of  
 672 concept-driven nomenclature is primarily the conceptual ‘why’, along with clarification of the  
 673 experimental ‘how’. Respiratory capacities delineate, comparable to channel capacity in  
 674 information theory (Schneider 2006), the upper bound of the rate of respiration measured in  
 675 defined coupling control states and electron transfer-pathway (ET-pathway) states (**Figure 5**).  
 676

677

678

678 **Figure 5. Four-compartment**  
 679 **model of oxidative**  
 680 **phosphorylation**

681 Respiratory states (ET,  
 682 OXPHOS, LEAK; **Table 1**) and  
 683 corresponding rates ( $E$ ,  $P$ ,  $L$ ) are  
 684 connected by the protonmotive  
 685 force,  $\Delta p$ . (1) ET-capacity,  $E$ , is  
 686 partitioned into (2) dissipative  
 687 LEAK-respiration,  $L$ , when the  
 688 Gibbs energy change of catabolic


689  $O_2$  flux is irreversibly lost, (3) net OXPHOS-capacity,  $P-L$ , with partial conservation of the  
 690 capacity to perform work, and (4) the excess capacity,  $E-P$ . Modified from Gnaiger (2014).  
 691

692

693

694 To provide a diagnostic reference for respiratory capacities of core energy metabolism,  
 695 the capacity of *oxidative phosphorylation*, OXPHOS, is measured at kinetically-saturating  
 696 concentrations of ADP and  $P_i$ . The *oxidative* ET-capacity reveals the limitation of OXPHOS-  
 697 capacity mediated by the *phosphorylation*-pathway. The ET- and phosphorylation-pathways  
 698 comprise coupled segments of the OXPHOS-system. ET-capacity is measured as noncoupled  
 699  $O_2$  consumption is studied by preventing the stimulation of phosphorylation either in the  
 700 absence of ADP or by inhibition of the phosphorylation-pathway. The corresponding states are  
 701 collectively classified as LEAK-states, when  $O_2$  consumption compensates mainly for ion  
 702 leaks, including the proton leak. Defined coupling states are induced by: (1) adding cation  
 703 chelators such as EGTA, binding free  $Ca^{2+}$  and thus limiting cation cycling; (2) adding ADP  
 704 and  $P_i$ ; (3) inhibiting the phosphorylation-pathway; and (4) uncoupler titrations, while  
 705 maintaining a defined ET-pathway state with constant fuel substrates and inhibitors of specific  
 706 branches of the ET-pathway (**Figure 5**).


707 The three coupling states, ET, LEAK and OXPHOS, are shown schematically with the  
 708 corresponding respiratory rates, abbreviated as  $E$ ,  $L$  and  $P$ , respectively (**Figure 5**). We  
 709 distinguish metabolic *pathways* from metabolic *states* and the corresponding metabolic *rates*;  
 710 for example: ET-pathways, ET-states, and ET-capacities,  $E$ , respectively (**Table 1**). The  
 711 protonmotive force is *high* in the OXPHOS-state when it drives phosphorylation, *maximum* in  
 712 the LEAK-state of coupled mitochondria, driven by LEAK-respiration at a minimum back-flux  
 713 of cations to the matrix side, and *very low* in the ET-state when uncouplers short-circuit the  
 714 proton cycle (**Table 1**).



715 **LEAK-state (Figure 6A):**  
 716 The LEAK-state is defined as a  
 717 state of mitochondrial respiration  
 718 when  $O_2$  flux mainly  
 719 compensates for ion leaks in the  
 720 absence of ATP synthesis, at  
 721 kinetically-saturating  
 722 concentrations of  $O_2$ , respiratory  
 723 fuel substrates and  $P_i$ . LEAK-  
 724 respiration is measured to obtain  
 725 an estimate of *intrinsic*  
 726 *uncoupling* without addition of an  
 727 experimental uncoupler: (1) in the  
 728 absence of adenylates, *i.e.*, AMP,  
 729 ADP and ATP; (2) after depletion  
 730 of ADP at a maximum ATP/ADP  
 731 ratio; or (3) after inhibition of the  
 732 phosphorylation-pathway by  
 733 inhibitors of F-ATPase—such as  
 734 oligomycin, or of adenine  
 735 nucleotide translocase—such as  
 736 carboxyatractyloside.  
 737 Adjustment of the nominal  
 738 concentration of these inhibitors  
 739 to the density of biological  
 740 sample applied can minimize or  
 741 avoid inhibitory side-effects  
 742 exerted on ET-capacity or even  
 743 some dyscoupling.

744 • **Proton leak and uncoupled respiration:**

745 The intrinsic proton leak is  
 746 the *uncoupled* leak current  
 747 of protons in which  
 748 protons diffuse across the  
 749 mtIM in the dissipative  
 750 direction of the downhill  
 751 protonmotive  
 752 force  
 753 without coupling to  
 754 phosphorylation (Figure  
 755 6A). The proton leak flux  
 756 depends non-linearly on  
 757 the protonmotive force  
 758 (Garlid *et al.* 1989;  
 759 Divakaruni and Brand  
 760 2011), it is a temperature-  
 761 dependent property of the  
 762 mtIM and may be enhanced  
 763 due to possible contaminations  
 764 by free fatty acids. Inducible  
 765 uncoupling mediated by uncoupling  
 protein 1 (UCP1) is physiologically  
 controlled, *e.g.*, in brown  
 adipose tissue. UCP1 is a  
 member of the mitochondrial  
 carrier family that is involved  
 in the translocation of protons  
 across the mtIM (Klingenberg  
 2017).



**Figure 6. Respiratory coupling states**

(A) **LEAK-state and rate, L:** Phosphorylation is arrested,  $J_{P\gg} = 0$ , and catabolic  $O_2$  flux,  $J_{kO_2,L}$ , is controlled mainly by the proton leak,  $J_{mH^{+neg},L}$ , at maximum protonmotive force (Figure 4). Extramitochondrial ATP may be hydrolyzed by extramitochondrial ATPases,  $J_{P\ll}$ .

(B) **OXPHOS-state and rate, P:** Phosphorylation,  $J_{P\gg}$ , is stimulated by kinetically-saturating  $[ADP]$  and  $[P_i]$ , and is supported by a high protonmotive force.  $O_2$  flux,  $J_{kO_2,P}$ , is well-coupled at a  $P\gg/O_2$  ratio of  $J_{P\gg,P}/J_{kO_2,P}$ . Extramitochondrial ATPases may recycle ATP,  $J_{P\ll}$ .

(C) **ET-state and rate, E:** Noncoupled respiration,  $J_{kO_2,E}$ , is maximum at optimum exogenous uncoupler concentration and phosphorylation is zero,  $J_{P\gg} = 0$ . The F-ATPase may hydrolyze extramitochondrial ATP. See also Figure 3.



766 Consequently, the short-circuit diminishes the protonmotive force and stimulates electron  
767 transfer to O<sub>2</sub> and heat dissipation without phosphorylation of ADP.

768 • **Cation cycling:** There can be other cation contributors to leak current including calcium  
769 and probably magnesium. Calcium influx is balanced by mitochondrial Na<sup>+</sup>/Ca<sup>2+</sup> or  
770 H<sup>+</sup>/Ca<sup>2+</sup> exchange, which is balanced by Na<sup>+</sup>/H<sup>+</sup> or K<sup>+</sup>/H<sup>+</sup> exchanges. This is another  
771 effective uncoupling mechanism different from proton leak (**Table 2**).

772

773 **Table 1. Coupling states and residual oxygen consumption in mitochondrial**  
774 **preparations in relation to respiration- and phosphorylation-flux,  $J_{kO_2}$  and  $J_{P\gg}$ ,**  
775 **and protonmotive force,  $\Delta p$ .** Coupling states are established at kinetically-  
776 saturating concentrations of fuel substrates and O<sub>2</sub>.

State	$J_{kO_2}$	$J_{P\gg}$	$\Delta p$	Inducing factors	Limiting factors
LEAK	$L$ ; low, cation leak-dependent respiration	0	max.	back-flux of cations including proton leak, proton slip	$J_{P\gg} = 0$ : (1) without ADP, $L_N$ ; (2) max. ATP/ADP ratio, $L_T$ ; or (3) inhibition of the phosphorylation-pathway, $L_{Omy}$
OXPHOS	$P$ ; high, ADP-stimulated respiration	max.	high	kinetically-saturating [ADP] and [P <sub>i</sub> ]	$J_{P\gg}$ by phosphorylation-pathway; or $J_{kO_2}$ by ET-capacity
ET	$E$ ; max., noncoupled respiration	0	low	optimal external uncoupler concentration for max. $J_{O_2,E}$	$J_{kO_2}$ by ET-capacity
ROX	$R_{ox}$ ; min., residual O <sub>2</sub> consumption	0	0	$J_{O_2,Rox}$ in non-ET-pathway oxidation reactions	inhibition of all ET-pathways; or absence of fuel substrates

777

778 • **Proton slip and decoupled respiration:** Proton slip is the *decoupled* process in which  
779 protons are only partially translocated by a redox proton pump of the ET-pathways and  
780 slip back to the original vesicular compartment. The proton leak is the dominant  
781 contributor to the overall leak current in mammalian mitochondria incubated under  
782 physiological conditions at 37 °C, whereas proton slip is increased at lower experimental  
783 temperature (Canton *et al.* 1995). Proton slip can also happen in association with the F-  
784 ATPase, in which the proton slips downhill across the pump to the matrix without  
785 contributing to ATP synthesis. In each case, proton slip is a property of the proton pump  
786 and increases with the pump turnover rate.

787 • **Electron leak and loosely coupled respiration:** Superoxide production by the ETS leads  
788 to a bypass of redox proton pumps and correspondingly lower P<sub>»</sub>/O<sub>2</sub> ratio. This depends  
789 on the actual site of electron leak and the scavenging of hydrogen peroxide by cytochrome  
790 *c*, whereby electrons may re-enter the ETS with proton translocation by CIV.

791 • **Loss of compartmental integrity and acoupled respiration:** Electron transfer and  
792 catabolic O<sub>2</sub> flux proceed without compartmental proton translocation in disrupted  
793 mitochondrial fragments. Such fragments form during mitochondrial isolation, and may  
794 not fully fuse to re-establish structurally intact mitochondria. Loss of mtIM integrity,  
795 therefore, is the cause of acoupled respiration, which is a nonvectorial dissipative process  
796 without control by the protonmotive force.

- 797 • **Dyscoupled respiration:** Mitochondrial injuries may lead to *dyscoupling* as a  
 798 pathological or toxicological cause of *uncoupled* respiration. Dyscoupling may involve  
 799 any type of uncoupling mechanism, *e.g.*, opening the permeability transition pore.  
 800 Dyscoupled respiration is distinguished from the experimentally induced *noncoupled*  
 801 respiration in the ET-state (**Table 2**).  
 802  
 803

**Table 2. Terms on respiratory coupling and uncoupling.**

Term	$J_{kO_2}$	$P_{\gg}/O_2$	Note	
acoupled		0	electron transfer in mitochondrial fragments without vectorial proton translocation ( <b>Figure 4</b> )	
intrinsic, no protonophore added	uncoupled	$L$	0	non-phosphorylating LEAK-respiration ( <b>Figure 6A</b> )
	proton leak-uncoupled		0	component of $L$ , $H^+$ diffusion across the mtIM ( <b>Figure 4</b> )
	decoupled		0	component of $L$ , proton slip ( <b>Figure 4</b> )
	loosely coupled		0	component of $L$ , lower coupling due to superoxide formation and bypass of proton pumps by electron leak ( <b>Figure 4</b> )
	dyscoupled		0	pathologically, toxicologically, environmentally increased uncoupling, mitochondrial dysfunction
	inducibly uncoupled		0	by UCP1 or cation ( <i>e.g.</i> , $Ca^{2+}$ ) cycling ( <b>Figure 4</b> )
noncoupled	$E$	0	non-phosphorylating respiration stimulated to maximum flux at optimum exogenous uncoupler concentration ( <b>Figure 6C</b> )	
well-coupled	$P$	high	phosphorylating respiration with an intrinsic LEAK component ( <b>Figure 6B</b> )	
fully coupled	$P - L$	max.	OXPHOS-capacity corrected for LEAK-respiration ( <b>Figure 5</b> )	

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

**OXPHOS-state (Figure 6B):** The OXPHOS-state is defined as the respiratory state with kinetically-saturating concentrations of  $O_2$ , respiratory and phosphorylation substrates, and absence of exogenous uncoupler, which provides an estimate of the maximal respiratory capacity in the OXPHOS-state for any given ET-pathway state. Respiratory capacities at kinetically-saturating substrate concentrations provide reference values or upper limits of performance, aiming at the generation of data sets for comparative purposes. Physiological activities and effects of substrate kinetics can be evaluated relative to the OXPHOS-capacity.

As discussed previously, 0.2 mM ADP does not fully saturate flux in isolated mitochondria (Gnaiger 2001; Puchowicz *et al.* 2004); greater ADP concentration is required, particularly in permeabilized muscle fibres and cardiomyocytes, to overcome limitations by intracellular diffusion and by the reduced conductance of the mtOM (Jepihhina *et al.* 2011, Illaste *et al.* 2012, Simson *et al.* 2016), either through interaction with tubulin (Rostovtseva *et al.* 2008) or other intracellular structures (Birkedal *et al.* 2014). In addition, saturating ADP concentrations need to be evaluated under different experimental conditions such as temperature (Lemieux *et al.* 2017) and with different animal models (Blier and Guderley,

1993). In permeabilized muscle fibre bundles of high respiratory capacity, the apparent  $K_m$  for ADP increases up to 0.5 mM (Saks *et al.* 1998), consistent with experimental evidence that >90% saturation is reached only at >5 mM ADP (Pesta and Gnaiger 2012). Similar ADP concentrations are also required for accurate determination of OXPHOS-capacity in human clinical cancer samples and permeabilized cells (Klepinin *et al.* 2016; Koit *et al.* 2017). Whereas 2.5 to 5 mM ADP is sufficient to obtain the actual OXPHOS-capacity in many types of permeabilized tissue and cell preparations, experimental validation is required in each specific case.

**Electron transfer-state (Figure 6C):**  $O_2$  flux determined in the ET-state yields an estimate of ET-capacity. The ET-state is defined as the *noncoupled* state with kinetically-saturating concentrations of  $O_2$ , respiratory substrate and optimum *exogenous* uncoupler concentration for maximum  $O_2$  flux. As a consequence of the nearly collapsed protonmotive force, the driving force is insufficient for phosphorylation, and  $J_{P\gg} = 0$ . The most frequently used uncouplers are carbonyl cyanide *m*-chloro phenyl hydrazone (CCCP), carbonyl cyanide *p*-trifluoromethoxyphenylhydrazone (FCCP), or dinitrophenole (DNP). Stepwise titration of uncouplers stimulates respiration up to or above the level of  $O_2$  consumption rates in the OXPHOS-state, but inhibition of respiration is observed above optimum uncoupler concentrations (Mitchell 2011). Data obtained with a single dose of uncoupler must be evaluated with caution, particularly when a fixed uncoupler concentration is used in studies exploring a treatment or disease that may alter the mitochondrial content or mitochondrial sensitivity to inhibition by uncouplers. The effect on ET-capacity of the reversed function of F-ATPase ( $J_{P\ll}$ ; Figure 6C) can be evaluated in the presence and absence of extramitochondrial ATP.

**ROX state and *Rox*:** Besides the three fundamental coupling states of mitochondrial preparations, the state of residual  $O_2$  consumption, ROX, is relevant to assess respiratory function (Figure 1). ROX is not a coupling state. The rate of residual oxygen consumption, *Rox*, is defined as  $O_2$  consumption due to oxidative reactions measured after inhibition of ET—with rotenone, malonic acid and antimycin A. Cyanide and azide inhibit not only CIV but catalase and several peroxidases involved in *Rox*. However, high concentrations of antimycin A, but not rotenone or cyanide, inhibit peroxisomal acyl-CoA oxidase and D-amino acid oxidase (Vamecq *et al.* 1987). ROX represents a baseline that is used to correct respiration measured in defined coupling states. *Rox*-corrected  $L$ ,  $P$  and  $E$  not only lower the values of total fluxes, but also changes the flux control ratios  $L/P$  and  $L/E$ . *Rox* is not necessarily equivalent to non-mitochondrial reduction of  $O_2$ , considering  $O_2$ -consuming reactions in mitochondria that are not related to ET—such as  $O_2$  consumption in reactions catalyzed by monoamine oxidases (type A and B), monooxygenases (cytochrome P450 monooxygenases), dioxygenase (sulfur dioxygenase and trimethyllysine dioxygenase), and several hydroxylases. Even isolated mitochondrial fractions, especially those obtained from liver, may be contaminated by peroxisomes. This fact makes the exact determination of mitochondrial  $O_2$  consumption and mitochondria-associated generation of reactive oxygen species complicated (Schönfeld *et al.* 2009; Speijer 2016; Figure 2). The dependence of ROX-linked  $O_2$  consumption needs to be studied in detail together with non-ET enzyme activities, availability of specific substrates,  $O_2$  concentration, and electron leakage leading to the formation of reactive oxygen species.

**Quantitative relations:**  $E$  may exceed or be equal to  $P$ .  $E > P$  is observed in many types of mitochondria, varying between species, tissues and cell types (Gnaiger 2009).  $E - P$  is the excess ET-capacity pushing the phosphorylation-flux (Figure 2C) to the limit of its *capacity of utilizing* the protonmotive force. In addition, the magnitude of  $E - P$  depends on the tightness of respiratory coupling or degree of uncoupling, since an increase of  $L$  causes  $P$  to increase towards the limit of  $E$ . The *excess*  $E - P$  capacity,  $E - P$ , therefore, provides a sensitive diagnostic indicator of specific injuries of the phosphorylation-pathway, under conditions when  $E$  remains constant but  $P$  declines relative to controls (Figure 5). Substrate cocktails supporting

872 simultaneous convergent electron transfer to the Q-junction for reconstitution of TCA cycle  
 873 function establish pathway control states with high ET-capacity, and consequently increase the  
 874 sensitivity of the *E-P* assay.

875 *E* cannot theoretically be lower than *P*.  $E < P$  must be discounted as an artefact, which  
 876 may be caused experimentally by: (1) loss of oxidative capacity during the time course of the  
 877 respirometric assay, since *E* is measured subsequently to *P*; (2) using insufficient uncoupler  
 878 concentrations; (3) using high uncoupler concentrations which inhibit ET (Gnaiger 2008); (4)  
 879 high oligomycin concentrations applied for measurement of *L* before titrations of uncoupler,  
 880 when oligomycin exerts an inhibitory effect on *E*. On the other hand, the excess ET-capacity is  
 881 overestimated if non-saturating [ADP] or [P<sub>i</sub>] are used. See State 3 in the next section.

882 The net OXPHOS-capacity is calculated by subtracting *L* from *P* (Figure 5). The net  
 883  $P \gg O_2$  equals  $P \gg (P-L)$ , wherein the dissipative LEAK component in the OXPHOS-state may  
 884 be overestimated. This can be avoided by measuring LEAK-respiration in a state when the  
 885 protonmotive force is adjusted to its slightly lower value in the OXPHOS-state—by titration of  
 886 an ET inhibitor (Divakaruni and Brand 2011). Any turnover-dependent components of proton  
 887 leak and slip, however, are underestimated under these conditions (Garlid *et al.* 1993). In  
 888 general, it is inappropriate to use the term *ATP production* or *ATP turnover* for the difference  
 889 of O<sub>2</sub> flux measured in the OXPHOS and LEAK states. *P-L* is the upper limit of OXPHOS-  
 890 capacity that is freely available for ATP production (corrected for LEAK-respiration) and is  
 891 fully coupled to phosphorylation with a maximum mechanistic stoichiometry (Figure 5).

892 The rates of LEAK respiration and OXPHOS capacity depend on (1) the tightness of  
 893 coupling under the influence of the respiratory uncoupling mechanisms (Figure 4), and (2) the  
 894 coupling stoichiometry, which varies as a function of the substrate type undergoing oxidation  
 895 in ET-pathways with either two or three coupling sites (Figure 2B). When cocktails with  
 896 NADH-linked substrates and succinate are used, the relative contribution of ET-pathways with  
 897 three or two coupling sites cannot be controlled experimentally, is difficult to determine, and  
 898 may shift in transitions between LEAK-, OXPHOS- and ET-states (Gnaiger 2014). Under these  
 899 experimental conditions, we cannot separate the tightness of coupling *versus* coupling  
 900 stoichiometry as the mechanisms of respiratory control in the shift of *L/P* ratios. The tightness  
 901 of coupling and fully coupled O<sub>2</sub> flux, *P-L* (Table 2), therefore, are obtained from  
 902 measurements of coupling control of LEAK respiration, OXPHOS- and ET-capacities in well  
 903 defined pathway states, using either pyruvate and malate as substrates or the classical succinate  
 904 and rotenone substrate-inhibitor combination (Figure 2B).

905

### 906 2.3. Classical terminology for isolated mitochondria

907 ‘When a code is familiar enough, it ceases appearing like a code; one forgets that there  
 908 is a decoding mechanism. The message is identical with its meaning’ (Hofstadter 1979).

909

910 Chance and Williams (1955; 1956) introduced five classical states of mitochondrial  
 911 respiration and cytochrome redox states. Table 3 shows a protocol with isolated mitochondria  
 912 in a closed respirometric chamber, defining a sequence of respiratory states. States and rates  
 913 are not specifically distinguished in this nomenclature.

914 **State 1** is obtained after addition of isolated mitochondria to air-saturated  
 915 isoosmotic/isotonic respiration medium containing P<sub>i</sub>, but no fuel substrates and no adenylates,  
 916 *i.e.*, AMP, ADP, ATP.

917 **State 2** is induced by addition of a ‘high’ concentration of ADP (typically 100 to 300  
 918 μM), which stimulates respiration transiently on the basis of endogenous fuel substrates and  
 919 phosphorylates only a small portion of the added ADP. State 2 is then obtained at a low  
 920 respiratory activity limited by exhausted endogenous fuel substrate availability (Table 3). If  
 921 addition of specific inhibitors of respiratory complexes—such as rotenone—does not cause a  
 922 further decline of O<sub>2</sub> flux, State 2 is equivalent to the ROX state (See below.). If inhibition is

923 observed, undefined endogenous fuel substrates are a confounding factor of pathway control,  
 924 contributing to the effect of subsequently externally added substrates and inhibitors. In contrast  
 925 to the original protocol, an alternative sequence of titration steps is frequently applied, in which  
 926 the alternative 'State 2' has an entirely different meaning, when this second state is induced by  
 927 addition of fuel substrate without ADP or ATP (LEAK-state; in contrast to State 2 defined in  
 928 **Table 1** as a ROX state). Some researchers have called this condition as "pseudostate 4"  
 929 because it has no significant concentrations of adenine nucleotides and hence it is not a near-  
 930 physiological condition, although it should be used for calculating the net OXPHOS-capacity,  
 931 *P-L*.

932  
 933 **Table 3. Metabolic states of mitochondria (Chance and**  
 934 **Williams, 1956; Table V).**  
 935

State	[O <sub>2</sub> ]	ADP level	Substrate level	Respiration rate	Rate-limiting substance
1	>0	low	low	slow	ADP
2	>0	high	~0	slow	substrate
3	>0	high	high	fast	respiratory chain
4	>0	low	high	slow	ADP
5	0	high	high	0	oxygen

936  
 937  
 938 **State 3** is the state stimulated by addition of fuel substrates while the ADP concentration  
 939 is still high (**Table 3**) and supports coupled energy transformation through oxidative  
 940 phosphorylation. 'High ADP' is a concentration of ADP specifically selected to allow the  
 941 measurement of State 3 to State 4 transitions of isolated mitochondria in a closed respirometric  
 942 chamber. Repeated ADP titration re-establishes State 3 at 'high ADP'. Starting at O<sub>2</sub>  
 943 concentrations near air-saturation (193 or 238 μM O<sub>2</sub> at 37 °C or 25 °C and sea level at 1 atm  
 944 or 101.32 kPa, and an oxygen solubility of respiration medium at 0.92 times that of pure water;  
 945 Forstner and Gnaiger 1983), the total ADP concentration added must be low enough (typically  
 946 100 to 300 μM) to allow phosphorylation to ATP at a coupled O<sub>2</sub> flux that does not lead to O<sub>2</sub>  
 947 depletion during the transition to State 4. In contrast, kinetically-saturating ADP concentrations  
 948 usually are 10-fold higher than 'high ADP', *e.g.*, 2.5 mM in isolated mitochondria. The  
 949 abbreviation State 3u is occasionally used in bioenergetics, to indicate the state of respiration  
 950 after titration of an uncoupler, without sufficient emphasis on the fundamental difference  
 951 between OXPHOS-capacity (*well-coupled* with an *endogenous* uncoupled component) and ET-  
 952 capacity (*noncoupled*).

953 **State 4** is a LEAK-state that is obtained only if the mitochondrial preparation is intact  
 954 and well-coupled. Depletion of ADP by phosphorylation to ATP causes a decline of O<sub>2</sub> flux in  
 955 the transition from State 3 to State 4. Under the conditions of State 4, a maximum protonmotive  
 956 force and high ATP/ADP ratio are maintained. The gradual decline of  $Y_{P_{\gg}/O_2}$  towards  
 957 diminishing [ADP] at State 4 must be taken into account for calculation of  $P_{\gg}/O_2$  ratios (Gnaiger  
 958 2001). State 4 respiration,  $L_T$  (**Table 1**), reflects intrinsic proton leak and ATP hydrolysis  
 959 activity. O<sub>2</sub> flux in State 4 is an overestimation of LEAK-respiration if the contaminating ATP  
 960 hydrolysis activity recycles some ATP to ADP,  $J_{P_{\ll}}$ , which stimulates respiration coupled to  
 961 phosphorylation,  $J_{P_{\gg}} > 0$ . Some degree of mechanical disruption and loss of mitochondrial  
 962 integrity allows the exposed mitochondrial F-ATPases to hydrolyze the ATP synthesized by  
 963 the fraction of coupled mitochondria. This can be tested by inhibition of the phosphorylation-  
 964 pathway using oligomycin, ensuring that  $J_{P_{\gg}} = 0$  (State 4o). On the other hand, the state 4  
 965 respiration reached after exhaustion of added ADP is a more physiological condition (*i.e.*,  
 966 presence of ATP, ADP and even AMP). Sequential ADP titrations re-establish State 3, followed

967 by State 3 to State 4 transitions while sufficient O<sub>2</sub> is available. Anoxia may be reached,  
968 however, before exhaustion of ADP (State 5).

969 **State 5** is the state after exhaustion of O<sub>2</sub> in a closed respirometric chamber. Diffusion of  
970 O<sub>2</sub> from the surroundings into the aqueous solution may be a confounding factor preventing  
971 complete anoxia (Gnaiger 2001). Chance and Williams (1955) provide an alternative definition  
972 of State 5, which gives it the different meaning of ROX versus anoxia: ‘State 5 may be obtained  
973 by antimycin A treatment or by anaerobiosis’.

974 In **Table 3**, only States 3 and 4 are coupling control states, with the restriction that rates  
975 in State 3 may be limited kinetically by non-saturating ADP concentrations.

976  
977

### 978 3. What is a rate?

979

980 A rate may be considered as the numerator and normalization as the complementary  
981 denominator, which are tightly linked in reporting the measurements in a format commensurate  
982 with the requirements of a database. Application of common and defined units is required for  
983 direct transfer of reported results into a database. The second [s] is the SI unit for the base  
984 quantity *time*. It is also the standard time-unit used in solution chemical kinetics.

985 The term *rate* is not adequately defined to be useful for reporting data. The inconsistency  
986 of the meanings of rate becomes apparent when considering Galileo Galilei’s famous principle,  
987 that ‘bodies of different weight all fall at the same rate (have a constant acceleration)’  
988 (Coopersmith 2010). A rate may be an extensive quantity, which is a *flow*, *I*, when expressed  
989 per object (per number of cells or organisms) or per chamber (per system). ‘System’ is defined  
990 as the open or closed chamber of the measuring device. A rate is a *flux*, *J*, when expressed as a  
991 size-specific quantity (**Figure 7A; Box 2**).

992

- 993 • **Extensive quantities:** An extensive quantity increases proportionally with system  
994 size. For example, mass and volume are extensive quantities. Flow is an extensive  
995 quantity. The magnitude of an extensive quantity is completely additive for non-  
996 interacting subsystems. The magnitude of these quantities depends on the extent or  
997 size of the system (Cohen *et al.* 2008).
- 998 • **Size-specific quantities:** ‘The adjective *specific* before the name of an extensive  
999 quantity is often used to mean *divided by mass*’ (Cohen *et al.* 2008). In this system-  
1000 paradigm, mass-specific flux is flow divided by mass of the *system* (the total mass of  
1001 everything within the measuring chamber or reactor). Rates are frequently expressed  
1002 as volume-specific flux. A mass-specific or volume-specific quantity is independent  
1003 of the extent of non-interacting homogenous subsystems. Tissue-specific quantities  
1004 (related to the *sample* in contrast to the *system*) are of fundamental interest in the field  
1005 of comparative mitochondrial physiology, where *specific* refers to the *type of the*  
1006 *sample* rather than *mass of the system*. The term *specific*, therefore, must be clarified;  
1007 *sample-specific*, *e.g.*, muscle mass-specific normalization, is distinguished from  
1008 *system-specific* quantities (mass or volume; **Figure 7**).
- 1009 • **Intensive quantities:** In contrast to size-specific properties, forces are *intensive*  
1010 quantities defined as the change of an extensive quantity per advancement of an  
1011 energy transformation (Gnaiger 1993b).

1012

1013  $N_X$  and  $m_X$  indicate the number format and mass format, respectively, for expressing the  
1014 quantity of a sample *X*. When different formats are indicated in symbols of derived quantities,  
1015 the format ( $\underline{N}$ ,  $\underline{m}$ ) is shown as a subscript (*underlined italic*), as in  $I_{O_2/\underline{N}X}$  and  $J_{O_2/\underline{m}X}$ . Oxygen flow  
1016 and flux are expressed in the molar format,  $n_{O_2}$  [mol], but in the volume format,  $V_{O_2}$  [m<sup>3</sup>] in

1017 ergometry. For mass-specific flux these formats can be distinguished as  $J_{\underline{m}O_2/\underline{m}X}$  and  $J_{\underline{V}O_2/\underline{m}X}$ ,  
 1018 respectively. Further examples are given in **Figure 7** and **Table 4**.


1019  
1020

1021 **Figure 7. Flow and flux, and**  
 1022 **normalization in structure-**  
 1023 **function analysis**

1024 (A) When expressing metabolic  
 1025 ‘rate’ measured in a chamber, a  
 1026 fundamental distinction is made  
 1027 between relating the rate to the  
 1028 experimental sample (left) or  
 1029 chamber (right). The different  
 1030 meanings of rate need to be  
 1031 specified by the chosen  
 1032 normalization. Left: Results are  
 1033 expressed as mass-specific *flux*,  
 1034  $J_{mX}$ , per mg protein, dry or wet  
 1035 weight (mass). Cell volume,  $V_{ce}$ ,  
 1036 may be used for normalization  
 1037 (volume-specific flux,  $J_{Vce}$ ).  
 1038 Right: Flow per chamber,  $I$ , or  
 1039 flux per chamber volume,  $J_V$ , are  
 1040 merely reported for  
 1041 methodological reasons.

1042 (B)  $O_2$  flow per cell,  $I_{O_2/Nce}$ , is the  
 1043 product of mitochondria-specific  
 1044 flux, mt-density and mass per  
 1045 cell. Unstructured analysis:  
 1046 performance is the product of  
 1047 mass-specific flux,  $J_{O_2/MX}$   
 1048 [ $\text{mol}\cdot\text{s}^{-1}\cdot\text{kg}^{-1}$ ], and *size* (mass per  
 1049 cell). Structured analysis:  
 1050 performance is the product of  
 1051 mitochondrial *function* (mt-  
 1052 specific flux) and *structure* (mt-  
 1053 content). Modified from Gnaiger  
 1054 (2014). For further details see  
 1055 **Table 4**.

1056  
1057



1058 **Box 2: Metabolic flows and fluxes: vectoral, vectorial, and scalar**  
 1059

1060 In a generalization of electrical terms, flow as an extensive quantity ( $I$ ; per system) is  
 1061 distinguished from flux as a size-specific quantity ( $J$ ; per system size). *Flows*,  $I_{tr}$ , are defined  
 1062 for all transformations as extensive quantities. Electric charge per unit time is electric flow or  
 1063 current,  $I_{el} = dQ_{el}\cdot dt^{-1}$  [ $A \equiv C\cdot s^{-1}$ ]. When dividing  $I_{el}$  by size of the system (cross-sectional area of a ‘wire’), we obtain flux as a size-specific quantity, which is the current density (surface-density of flow) perpendicular to the direction of flux,  $J_{el} = I_{el}\cdot A^{-1}$  [ $A\cdot m^{-2}$ ] (Cohen et al. 2008). Fluxes with *spatial* geometric direction and magnitude are *vectors*. Vector and scalar *fluxes* are related to flows as  $J_{tr} = I_{tr}\cdot A^{-1}$  [ $\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-2}$ ] and  $J_{tr} = I_{tr}\cdot V^{-1}$  [ $\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-3}$ ], expressing flux as an area-specific vector or volume-specific vectorial or scalar quantity, respectively (Gnaiger  
 1068

1069 1993b). We use the metre–kilogram–second–ampere (MKSA) international system of units (*SI*)  
 1070 for general cases ([m], [kg], [s] and [A]), with decimal *SI* prefixes for specific applications  
 1071 (**Table 4**).

1072 We suggest to define: (1) *vectorial* fluxes, which are translocations as functions of  
 1073 *gradients* with direction in geometric space in continuous systems; (2) *vectorial* fluxes, which  
 1074 describe translocations in discontinuous systems and are restricted to information on  
 1075 *compartmental differences* (**Figure 3**, transmembrane proton flux); and (3) *scalar* fluxes, which  
 1076 are transformations in a *homogenous* system (**Figure 3**, catabolic O<sub>2</sub> flux,  $J_{kO_2}$ ).

1077 Vectorial transmembrane proton fluxes,  $J_{mH^{+pos}}$  and  $J_{mH^{+neg}}$ , are analyzed in a  
 1078 heterogenous compartmental system as a quantity with *directional* but not *spatial* information.  
 1079 Translocation of protons across the mtIM has a defined direction, either from the negative  
 1080 compartment (matrix space; negative, neg–compartment) to the positive compartment (inter-  
 1081 membrane space; positive, pos–compartment) or *vice versa* (**Figure 3**). The arrows defining  
 1082 the direction of the translocation between the two vesicular compartments may point upwards  
 1083 or downwards, right or left, without any implication that these are actual directions in space.  
 1084 The pos–compartment is neither above nor below the neg–compartment in a spatial sense, but  
 1085 can be visualized arbitrarily in a figure in the upper position (**Figure 3**). In general, the  
 1086 *compartmental direction* of vectorial translocation from the neg–compartment to the pos–  
 1087 compartment is defined by assigning the initial and final state as *ergodynamic compartments*,  
 1088  $H^{+}_{neg} \rightarrow H^{+}_{pos}$  or  $0 = -1 H^{+}_{neg} + 1 H^{+}_{pos}$ , related to work (erg = work) that must be performed to  
 1089 lift the proton from a lower to a higher electrochemical potential or from the lower to the higher  
 1090 ergodynamic compartment (Gnaiger 1993b).

1091 In analogy to *vectorial* translocation, the direction of a *scalar* chemical reaction,  $A \rightarrow B$   
 1092 or  $0 = -1 A + 1 B$ , is defined by assigning substrates and products, A and B, as ergodynamic  
 1093 compartments. O<sub>2</sub> is defined as a substrate in respiratory O<sub>2</sub> consumption (electron acceptor),  
 1094 which together with the fuel substrates (electron donors) comprises the substrate compartment  
 1095 of the catabolic reaction. Volume-specific scalar O<sub>2</sub> flux is coupled to vectorial translocation,  
 1096 yielding the  $H^{+}_{pos}/O_2$  ratio (**Figure 2B**).

---

1097  
 1098

#### 1099 4. Normalization of rate per sample

1100

1101 The challenges of measuring mitochondrial respiratory flux are matched by those of  
 1102 normalization. Normalization (**Table 4**) is guided by physicochemical principles,  
 1103 methodological considerations, and conceptual strategies (**Figure 7**).

1104

##### 1105 4.1. Flow: per object

1106

1107 **Number concentration,  $C_{NX}$ :** Normalization per sample concentration is routinely  
 1108 required to report respiratory data.  $C_{NX}$  is the experimental *number concentration* of sample X.  
 1109 In the case of animals, e.g., nematodes,  $C_{NX} = N_X/V [x \cdot L^{-1}]$ , where  $N_X$  is the number of organisms  
 1110 in the chamber. Similarly, the number of cells per chamber volume is the number concentration  
 1111 of permeabilized or intact cells  $C_{Nce} = N_{ce}/V [x \cdot L^{-1}]$ , where  $N_{ce}$  is the number of cells in the  
 1112 chamber (**Table 4**).

1113 **Flow per object,  $I_{O_2/Nce}$ :** O<sub>2</sub> flow per cell is calculated from volume-specific O<sub>2</sub> flux,  $J_{V,O_2}$   
 1114 [nmol·s<sup>-1</sup>·L<sup>-1</sup>] (per  $V$  of the measurement chamber [L]), divided by the number concentration of  
 1115 cells. The total cell count is the sum of viable and dead cells,  $N_{ce} = N_{vce} + N_{dce}$  (**Table 5**). The  
 1116 cell viability index,  $VI = N_{vce}/N_{ce}$ , is the ratio of viable cells ( $N_{vce}$ ; before experimental  
 1117 permeabilization) per total cell count. After experimental permeabilization, all cells are  
 1118 permeabilized,  $N_{pce} = N_{ce}$ . The cell viability index can be used to normalize respiration for the  
 1119 number of cells that have been viable before experimental permeabilization,  $I_{O_2/Nvce} = I_{O_2/Nce}/VI$ ,



1120 considering that mitochondrial respiratory dysfunction in dead cells should be eliminated as a  
 1121 confounding factor.

1122

1123

1124

**Table 4. Sample concentrations and normalization of flux.**

Expression	Symbol	Definition	Unit	Notes
<b>Sample</b>				
identity of sample	$X$	object: cell, tissue, animal, patient		
number of sample entities $X$	$N_X$	number of objects	x	1
mass of sample $X$	$m_X$		kg	2
mass of object $X$	$M_X$	$M_X = m_X \cdot N_X^{-1}$	$\text{kg} \cdot \text{x}^{-1}$	2
<b>Mitochondria</b>				
Mitochondria	mt	$X = \text{mt}$		
amount of mt-elementary components	$mtE$	quantity of mt-marker	mtEU	
<b>Concentrations</b>				
object number concentration	$C_{NX}$	$C_{NX} = N_X \cdot V^{-1}$	$\text{x} \cdot \text{m}^{-3}$	3
sample mass concentration	$C_{mX}$	$C_{mX} = m_X \cdot V^{-1}$	$\text{kg} \cdot \text{m}^{-3}$	
mitochondrial concentration	$C_{mtE}$	$C_{mtE} = mtE \cdot V^{-1}$	$\text{mtEU} \cdot \text{m}^{-3}$	4
specific mitochondrial density	$D_{mtE}$	$D_{mtE} = mtE \cdot m_X^{-1}$	$\text{mtEU} \cdot \text{kg}^{-1}$	5
mitochondrial content, $mtE$ per object $X$	$mtE_{NX}$	$mtE_{NX} = mtE \cdot N_X^{-1}$	$\text{mtEU} \cdot \text{x}^{-1}$	6
<b>O<sub>2</sub> flow and flux</b>				
flow, system	$I_{O_2}$	internal flow	$\text{mol} \cdot \text{s}^{-1}$	7
volume-specific flux	$J_{V,O_2}$	$J_{V,O_2} = I_{O_2} \cdot V^{-1}$	$\text{mol} \cdot \text{s}^{-1} \cdot \text{m}^{-3}$	8
flow per object $X$	$I_{O_2/NX}$	$I_{O_2/NX} = J_{V,O_2} \cdot C_{NX}^{-1}$	$\text{mol} \cdot \text{s}^{-1} \cdot \text{x}^{-1}$	9
mass-specific flux	$J_{O_2/mX}$	$J_{O_2/mX} = J_{V,O_2} \cdot C_{mX}^{-1}$	$\text{mol} \cdot \text{s}^{-1} \cdot \text{kg}^{-1}$	10
mt-marker-specific flux	$J_{O_2/mtE}$	$J_{O_2/mtE} = J_{V,O_2} \cdot C_{mtE}^{-1}$	$\text{mol} \cdot \text{s}^{-1} \cdot \text{mtEU}^{-1}$	11

1125 1 The unit x for a number is not used by IUPAC. To avoid confusion, the units [ $\text{kg} \cdot \text{x}^{-1}$ ] and [kg]  
 1126 distinguish the mass per object from the mass of a sample that may contain any number of objects.  
 1127 Similarly, the units for flow per system *versus* flow per object are [ $\text{mol} \cdot \text{s}^{-1}$ ] (Note 8) and [ $\text{mol} \cdot \text{s}^{-1} \cdot \text{x}^{-1}$ ]  
 1128 (Note 10).

1129 2 Units are given in the MKSA system (**Box 2**). The *SI* prefix k is used for the *SI* base unit of mass (kg  
 1130 = 1,000 g). In praxis, various *SI* prefixes are used for convenience, to make numbers easily readable,  
 1131 e.g., 1 mg tissue, cell or mitochondrial mass instead of 0.000001 kg.

1132 3 In case of cells (sample  $X = \text{cells}$ ), the object number concentration is  $C_{N_{ce}} = N_{ce} \cdot V^{-1}$ , and volume  
 1133 may be expressed in [ $\text{dm}^3 \equiv \text{L}$ ] or [ $\text{cm}^3 = \text{mL}$ ]. See **Table 5** for different object types.

1134 4 mt-concentration is an experimental variable, dependent on sample concentration: (1)  $C_{mtE} = mtE \cdot V^{-1}$ ;  
 1135 (2)  $C_{mtE} = mtE_X \cdot C_{NX}$ ; (3)  $C_{mtE} = C_{mX} \cdot D_{mtE}$ .

1136 5 If the amount of mitochondria,  $mtE$ , is expressed as mitochondrial mass, then  $D_{mtE}$  is the mass  
 1137 fraction of mitochondria in the sample. If  $mtE$  is expressed as mitochondrial volume,  $V_{mt}$ , and the  
 1138 mass of sample,  $m_X$ , is replaced by volume of sample,  $V_X$ , then  $D_{mtE}$  is the volume fraction of  
 1139 mitochondria in the sample.

1140 6  $mtE_{NX} = mtE \cdot N_X^{-1} = C_{mtE} \cdot C_{NX}^{-1}$ .

1141 7 O<sub>2</sub> can be replaced by other chemicals B to study different reactions, e.g., ATP, H<sub>2</sub>O<sub>2</sub>, or vesicular  
 1142 compartmental translocations, e.g., Ca<sup>2+</sup>.

1143 8  $I_{O_2}$  and  $V$  are defined per instrument chamber as a system of constant volume (and constant  
 1144 temperature), which may be closed or open.  $I_{O_2}$  is abbreviated for  $I_{rO_2}$ , i.e., the metabolic or internal  
 1145 O<sub>2</sub> flow of the chemical reaction r in which O<sub>2</sub> is consumed, hence the negative stoichiometric  
 1146 number,  $\nu_{O_2} = -1$ .  $I_{rO_2} = d_r n_{O_2} / dt \cdot \nu_{O_2}^{-1}$ . If r includes all chemical reactions in which O<sub>2</sub> participates, then

- 1147  $d_r n_{O_2} = dn_{O_2} - d_e n_{O_2}$ , where  $dn_{O_2}$  is the change in the amount of  $O_2$  in the instrument chamber and  $d_e n_{O_2}$   
 1148 is the amount of  $O_2$  added externally to the system. At steady state, by definition  $dn_{O_2} = 0$ , hence  $d_r n_{O_2}$   
 1149  $= -d_e n_{O_2}$ .
- 1150 9  $J_{V,O_2}$  is an experimental variable, expressed per volume of the instrument chamber.
- 1151 10  $I_{O_2/NX}$  is a physiological variable, depending on the size of entity  $X$ .
- 1152 11 There are many ways to normalize for a mitochondrial marker, that are used in different experimental  
 1153 approaches: (1)  $J_{O_2/mtE} = J_{V,O_2} \cdot C_{mtE}^{-1}$ ; (2)  $J_{O_2/mtE} = J_{V,O_2} \cdot C_{mX}^{-1} \cdot D_{mtE}^{-1} = J_{O_2/mX} \cdot D_{mtE}^{-1}$ ; (3)  $J_{O_2/mtE} =$   
 1154  $J_{V,O_2} \cdot C_{NX}^{-1} \cdot mtE_{NX}^{-1} = I_{O_2/NX} \cdot mtE_{NX}^{-1}$ ; (4)  $J_{O_2/mtE} = I_{O_2} \cdot mtE^{-1}$ . The mt-elementary unit [mtEU] varies depending  
 1155 on the mt-marker.
- 1156  
 1157  
 1158 **Table 5. Sample types, X, abbreviations, and quantification.**

Identity of sample	$X$	$N_X$	Mass <sup>a</sup>	Volume	mt-Marker
mitochondrial preparation		[x]	[kg]	[m <sup>3</sup> ]	[mtEU]
isolated mitochondria	imt		$m_{mt}$	$V_{mt}$	$mtE$
tissue homogenate	thom		$m_{thom}$		$mtE_{thom}$
permeabilized tissue	pti		$m_{pti}$		$mtE_{pti}$
permeabilized fibre	pfi		$m_{pfi}$		$mtE_{pfi}$
permeabilized cell	pce	$N_{pce}$	$M_{pce}$	$V_{pce}$	$mtE_{pce}$
cells <sup>b</sup>	ce	$N_{ce}$	$M_{ce}$	$V_{ce}$	$mtE_{ce}$
intact cell, viable cell	vce	$N_{vce}$	$M_{vce}$	$V_{vce}$	
dead cell	dce	$N_{dce}$	$M_{dce}$	$V_{dce}$	
Organism	org	$N_{org}$	$M_{org}$	$V_{org}$	

1159 <sup>a</sup> Instead of mass, the wet weight or dry weight is frequently stated,  $W_w$  or  $W_d$ .  
 1160  $m_X$  is mass of the sample [kg],  $M_X$  is mass of the object [kg·x<sup>-1</sup>] (Table 4).

1161 <sup>b</sup> Total cell count,  $N_{ce} = N_{vce} + N_{dce}$

1162

1163 The complexity changes when the sample is a whole organism studied as an experimental  
 1164 model. The scaling law in respiratory physiology reveals a strong interaction between  $O_2$  flow  
 1165 and individual body mass, since *basal* metabolic rate (flow) does not increase linearly with  
 1166 body mass, whereas *maximum* mass-specific  $O_2$  flux,  $\dot{V}_{O_2max}$  or  $\dot{V}_{O_2peak}$ , is approximately  
 1167 constant across a large range of individual body mass (Weibel and Hoppeler 2005), with  
 1168 individuals, breeds, and species deviating substantially from this relationship.  $\dot{V}_{O_2peak}$  of human  
 1169 endurance athletes is 60 to 80 mL  $O_2 \cdot \text{min}^{-1} \cdot \text{kg}^{-1}$  body mass, converted to  $J_{O_2peak/Morg}$  of 45 to 60  
 1170 nmol·s<sup>-1</sup>·g<sup>-1</sup> (Gnaiger 2014; Table 6).

1171

#### 1172 4.2. Size-specific flux: per sample size

1173

1174 **Sample concentration,  $C_{mX}$ :** Considering permeabilized tissue, homogenate or cells as  
 1175 the sample,  $X$ , the sample mass is  $m_X$  [mg], which is frequently measured as wet or dry weight,  
 1176  $W_w$  or  $W_d$  [mg], respectively, or as amount of protein,  $m_{Protein}$ . The sample concentration is the  
 1177 mass of the subsample per volume of the measurement chamber,  $C_{mX} = m_X/V$  [g·L<sup>-1</sup> = mg·mL<sup>-1</sup>].  
 1178  $X$  is the type of sample—isolated mitochondria, tissue homogenate, permeabilized fibres or  
 1179 cells (Table 5).

1180 **Size-specific flux:** Cellular  $O_2$  flow can be compared between cells of identical size. To  
 1181 take into account changes and differences in cell size, normalization is required to obtain cell  
 1182 size-specific or mitochondrial marker-specific  $O_2$  flux (Renner *et al.* 2003).

- 1183 • **Mass-specific flux,  $J_{O_2/mX}$  [mol·s<sup>-1</sup>·kg<sup>-3</sup>]:** Mass-specific flux is obtained by expressing  
 1184 respiration per mass of sample,  $m_X$  [mg]. Flow per cell is divided by mass per cell,

1185  $J_{O_2/mce} = I_{O_2/Nce}/M_{Nce}$ . Or chamber volume-specific flux,  $J_{V,O_2}$ , is divided by mass  
 1186 concentration of  $X$  in the chamber,  $J_{O_2/mX} = J_{V,O_2}/C_{mX}$ .

- 1187 • **Cell volume-specific flux,  $J_{O_2/VX}$  [ $\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-3}$ ]**: Sample volume-specific flux is  
 1188 obtained by expressing respiration per volume of sample. For example, in the case of  
 1189 using cells as sample will be the volume of cells added to the chamber (**Figure 7**).

1190  
 1191 If size-specific  $O_2$  flux is constant and independent of sample size, then there is no  
 1192 interaction between the subsystems. For example, a 1.5 mg and a 3.0 mg muscle sample respires  
 1193 at identical mass-specific flux. Mass-specific  $O_2$  flux, however, may change with the mass of a  
 1194 tissue sample, cells or isolated mitochondria in the measuring chamber, in which the nature of  
 1195 the interaction becomes an issue. Therefore, cell density must be optimized, particularly in  
 1196 experiments carried out in wells, considering the confluency of the cell monolayer or clumps  
 1197 of cells (Salabei *et al.* 2014).

#### 1198 4.3. Marker-specific flux: per mitochondrial content

1200  
 1201 Tissues can contain multiple cell populations that may have distinct mitochondrial  
 1202 subtypes. Mitochondria undergo dynamic fission and fusion cycles, and can exist in multiple  
 1203 stages and sizes that may be altered by a range of factors. The isolation of mitochondria (often  
 1204 achieved through differential centrifugation) can therefore yield a subsample of the  
 1205 mitochondrial types present in a tissue, depending on the isolation protocols utilized (*e.g.*,  
 1206 centrifugation speed). This possible bias should be taken into account when planning  
 1207 experiments using isolated mitochondria. Different sizes of mitochondria are enriched at  
 1208 specific centrifugation speeds, which can be used strategically for isolation of mitochondrial  
 1209 subpopulations.

1210 Part of the mitochondrial content of a tissue is lost during preparation of isolated  
 1211 mitochondria. The fraction of isolated mitochondria obtained from a tissue sample is expressed  
 1212 as mitochondrial recovery. At a high mitochondrial recovery the fraction of isolated  
 1213 mitochondria is more representative of the total mitochondrial population than in preparations  
 1214 characterized by low recovery. Determination of the mitochondrial recovery and yield is based  
 1215 on measurement of the concentration of a mitochondrial marker in the stock of isolated  
 1216 mitochondria,  $C_{mtE,stock}$ , and crude tissue homogenate,  $C_{mtE,thom}$ , which simultaneously provides  
 1217 information on the specific mitochondrial density in the sample,  $D_{mtE}$  (**Table 4**).

1218 Normalization is a problematic subject; it is essential to consider the question of the study.  
 1219 If the study aims at comparing tissue performance—such as the effects of a treatment on a  
 1220 specific tissue, then normalization for tissue mass or protein content is appropriate. However,  
 1221 if the aim is to find differences on mitochondrial function independent of mitochondrial density  
 1222 (**Table 4**), then normalization to a mitochondrial marker is imperative (**Figure 7**). One cannot  
 1223 assume that quantitative changes in various markers—such as mitochondrial proteins—  
 1224 necessarily occur in parallel with one another. It should be established that the marker chosen  
 1225 is not selectively altered by the performed treatment. In conclusion, the normalization must  
 1226 reflect the question under investigation to reach a satisfying answer. On the other hand, the goal  
 1227 of comparing results across projects and institutions requires standardization on normalization  
 1228 for entry into a databank.

1229 **Mitochondrial concentration,  $C_{mtE}$ , and mitochondrial markers:** Mitochondrial  
 1230 organelles comprise a dynamic cellular reticulum in various states of fusion and fission. Hence,  
 1231 the definition of an "amount" of mitochondria is often misconceived: mitochondria cannot be  
 1232 counted reliably as a number of occurring elementary components. Therefore, quantification of  
 1233 the "amount" of mitochondria depends on the measurement of chosen mitochondrial markers.  
 1234 'Mitochondria are the structural and functional elementary units of cell respiration' (Gnaiger  
 1235 2014). The quantity of a mitochondrial marker can reflect the amount of *mitochondrial*

1236 *elementary components, mtE*, expressed in various mitochondrial elementary units [mtEU]  
 1237 specific for each measured mt-marker (**Table 4**). However, since mitochondrial quality may  
 1238 change in response to stimuli—particularly in mitochondrial dysfunction (Campos *et al.* 2017)  
 1239 and after exercise training (Pesta *et al.* 2011) and during aging (Daum *et al.* 2013)—some  
 1240 markers can vary while others are unchanged: (1) Mitochondrial volume and membrane area  
 1241 are structural markers, whereas mitochondrial protein mass is frequently used as a marker for  
 1242 isolated mitochondria. (2) Molecular and enzymatic mitochondrial markers (amounts or  
 1243 activities) can be selected as matrix markers, *e.g.*, citrate synthase activity, mtDNA; mtIM-  
 1244 markers, *e.g.*, cytochrome *c* oxidase activity, *aa*<sub>3</sub> content, cardiolipin, or mtOM-markers, *e.g.*,  
 1245 the voltage-dependent anion channel (VDAC), TOM20. (3) Extending the measurement of  
 1246 mitochondrial marker enzyme activity to mitochondrial pathway capacity, ET- or OXPHOS-  
 1247 capacity can be considered as an integrative functional mitochondrial marker.

1248 Depending on the type of mitochondrial marker, the mitochondrial elementary  
 1249 component, *mtE*, is expressed in marker-specific units. Mitochondrial concentration in the  
 1250 measurement chamber and the tissue of origin are quantified as (1) a quantity for normalization  
 1251 in functional analyses,  $C_{mtE}$ , and (2) a physiological output that is the result of mitochondrial  
 1252 biogenesis and degradation,  $D_{mtE}$ , respectively (**Table 4**). It is recommended, therefore, to  
 1253 distinguish *experimental mitochondrial concentration*,  $C_{mtE} = mtE/V$  and *physiological*  
 1254 *mitochondrial density*,  $D_{mtE} = mtE/m_X$ . Then mitochondrial density is the amount of  
 1255 mitochondrial elementary components per mass of tissue, which is a biological variable (**Figure**  
 1256 **7**). The experimental variable is mitochondrial density multiplied by sample mass concentration  
 1257 in the measuring chamber,  $C_{mtE} = D_{mtE} \cdot C_{mX}$ , or mitochondrial content multiplied by sample  
 1258 number concentration,  $C_{mtE} = mtE_X \cdot C_{NX}$  (**Table 4**).

1259 **mt-Marker-specific flux,  $J_{O_2/mtE}$** : Volume-specific metabolic O<sub>2</sub> flux depends on: (1) the  
 1260 sample concentration in the volume of the instrument chamber,  $C_{mX}$ , or  $C_{NX}$ ; (2) the  
 1261 mitochondrial density in the sample,  $D_{mtE} = mtE/m_X$  or  $mtE_X = mtE/N_X$ ; and (3) the specific  
 1262 mitochondrial activity or performance per elementary mitochondrial unit,  $J_{O_2/mtE} = J_{V,O_2}/C_{mtE}$   
 1263 [ $\text{mol}\cdot\text{s}^{-1}\cdot\text{mtEU}^{-1}$ ] (**Table 4**). Obviously, the numerical results for  $J_{O_2/mtE}$  vary with the type of  
 1264 mitochondrial marker chosen for measurement of *mtE* and  $C_{mtE} = mtE/V$  [ $\text{mtEU}\cdot\text{m}^{-3}$ ].

1265 Different methods are implicated in the quantification of mitochondrial markers and have  
 1266 different strengths. Some problems are common for all mitochondrial markers, *mtE*: (1)  
 1267 Accuracy of measurement is crucial, since even a highly accurate and reproducible  
 1268 measurement of O<sub>2</sub> flux results in an inaccurate and noisy expression if normalized by a biased  
 1269 and noisy measurement of a mitochondrial marker. This problem is acute in mitochondrial  
 1270 respiration because the denominators used (the mitochondrial markers) are often small moieties  
 1271 of which accurate and precise determination is difficult. This problem can be avoided when O<sub>2</sub>  
 1272 fluxes measured in substrate-uncoupler-inhibitor titration protocols are normalized for flux in  
 1273 a defined respiratory reference state, which is used as an *internal* marker and yields flux control  
 1274 ratios, *FCRs*. *FCRs* are independent of *externally* measured markers and, therefore, are  
 1275 statistically robust, considering the limitations of ratios in general (Jasienski and Bazzaz 1999).  
 1276 *FCRs* indicate qualitative changes of mitochondrial respiratory control, with highest  
 1277 quantitative resolution, separating the effect of mitochondrial density or concentration on  $J_{O_2/mX}$   
 1278 and  $I_{O_2/NX}$  from that of function per elementary mitochondrial marker,  $J_{O_2/mtE}$  (Pesta *et al.* 2011;  
 1279 Gnaiger 2014). (2) If mitochondrial quality does not change and only the amount of  
 1280 mitochondria varies as a determinant of mass-specific flux, any marker is equally qualified in  
 1281 principle; then in practice selection of the optimum marker depends only on the accuracy and  
 1282 precision of measurement of the mitochondrial marker. (3) If mitochondrial flux control ratios  
 1283 change, then there may not be any best mitochondrial marker. In general, measurement of  
 1284 multiple mitochondrial markers enables a comparison and evaluation of normalization for a  
 1285 variety of mitochondrial markers. Particularly during postnatal development, the activity of  
 1286 marker enzymes—such as cytochrome *c* oxidase and citrate synthase—follows different time

1287 courses (Drahota *et al.* 2004). Evaluation of mitochondrial markers in healthy controls is  
1288 insufficient for providing guidelines for application in the diagnosis of pathological states and  
1289 specific treatments.

1290 In line with the concept of the respiratory control ratio (Chance and Williams 1955a), the  
1291 most readily used normalization is that of flux control ratios and flux control factors (Gnaiger  
1292 2014). Selection of the state of maximum flux in a protocol as the reference state has the  
1293 advantages of: (1) internal normalization; (2) statistically validated linearization of the response  
1294 in the range of 0 to 1; and (3) consideration of maximum flux for integrating a large number of  
1295 elementary steps in the OXPHOS- or ET-pathways. This reduces the risk of selecting a  
1296 functional marker that is specifically altered by the treatment or pathology, yet increases the  
1297 chance that the highly integrative pathway is disproportionately affected, *e.g.*, the OXPHOS-  
1298 rather than ET-pathway in case of an enzymatic defect in the phosphorylation-pathway. In this  
1299 case, additional information can be obtained by reporting flux control ratios based on a  
1300 reference state which indicates stable tissue-mass specific flux.

1301 Stereological determination of mitochondrial content via two-dimensional transmission  
1302 electron microscopy can have limitations due to the dynamics of mitochondrial size (Meinild  
1303 Lundby *et al.* 2017). Accurate determination of three-dimensional volume by two-dimensional  
1304 microscopy can be both time consuming and statistically challenging (Larsen *et al.* 2012).

1305 The validity of using mitochondrial marker enzymes (citrate synthase activity, CI to CIV  
1306 amount or activity) for normalization of flux is limited in part by the same factors that apply to  
1307 flux control ratios. Strong correlations between various mitochondrial markers and citrate  
1308 synthase activity (Reichmann *et al.* 1985; Boushel *et al.* 2007; Mogensen *et al.* 2007) are  
1309 expected in a specific tissue of healthy persons and in disease states not specifically targeting  
1310 citrate synthase. Citrate synthase activity is acutely modifiable by exercise (Tonkonogi *et al.*  
1311 1997; Leek *et al.* 2001). Evaluation of mitochondrial markers related to a selected age and sex  
1312 cohort cannot be extrapolated to provide recommendations for normalization in respirometric  
1313 diagnosis of disease, in different states of development and ageing, different cell types, tissues,  
1314 and species. mtDNA normalized to nDNA via qPCR is correlated to functional mitochondrial  
1315 markers including OXPHOS- and ET-capacity in some cases (Puntschart *et al.* 1995; Wang *et al.*  
1316 1999; Menshikova *et al.* 2006; Boushel *et al.* 2007; Ehinger *et al.* 2015), but lack of such  
1317 correlations have been reported (Menshikova *et al.* 2005; Schultz and Wiesner 2000; Pesta *et al.*  
1318 2011). Several studies indicate a strong correlation between cardiolipin content and increase  
1319 in mitochondrial function with exercise (Menshikova *et al.* 2005; Menshikova *et al.* 2007;  
1320 Larsen *et al.* 2012; Faber *et al.* 2014), but it has not been evaluated as a general mitochondrial  
1321 biomarker in disease. With no single best mitochondrial marker, a good strategy is to quantify  
1322 several different biomarkers to minimize the decorrelating effects caused by diseases,  
1323 treatments, or other factors. Determination of multiple markers, particularly a matrix marker  
1324 and a marker from the mtIM, allows tracking changes in mitochondrial quality defined by their  
1325 ratio.

1326

1327

## 1328 **5. Normalization of rate per system**

1329

### 1330 *5.1. Flow: per chamber*

1331

1332 The experimental system (experimental chamber) is part of the measurement instrument,  
1333 separated from the environment as an isolated, closed, open, isothermal or non-isothermal  
1334 system (**Table 4**). Reporting O<sub>2</sub> flows per respiratory chamber,  $I_{O_2}$  [nmol·s<sup>-1</sup>], restricts the  
1335 analysis to intra-experimental comparison of relative differences.

1336

1337

## 1338 5.2. Flux: per chamber volume

1339  
1340 **System-specific flux,  $J_{V,O_2}$ :** We distinguish between (1) the *system* with volume  $V$  and  
1341 mass  $m$  defined by the system boundaries, and (2) the *sample* or *objects* with volume  $V_X$  and  
1342 mass  $m_X$  that are enclosed in the experimental chamber (Figure 7). Metabolic  $O_2$  flow per  
1343 object,  $I_{O_2/NX}$ , is the total  $O_2$  flow in the system divided by the number of objects,  $N_X$ , in the  
1344 system.  $I_{O_2/NX}$  increases as the mass of the object is increased. Sample mass-specific  $O_2$  flux,  
1345  $J_{O_2/mX}$  should be independent of the mass of the sample studied in the instrument chamber, but  
1346 system volume-specific  $O_2$  flux,  $J_{V,O_2}$  (per volume of the instrument chamber), increases in  
1347 proportion to the mass of the sample in the chamber. Whereas  $J_{V,O_2}$  depends on mass-  
1348 concentration of the sample in the chamber, it should be independent of the chamber (system)  
1349 volume at constant sample mass. There are practical limitations to increase the mass-  
1350 concentration of the sample in the chamber, when one is concerned about crowding effects and  
1351 instrumental time resolution.

1352 **Advancement per volume:** When the reactor volume does not change during the  
1353 reaction, which is typical for liquid phase reactions, the volume-specific flux of a chemical  
1354 reaction  $r$  is the time derivative of the advancement of the reaction per unit volume,  $J_{V,rB} =$   
1355  $d_{t,r}c_B/dt \cdot V^{-1}$  [(mol·s<sup>-1</sup>)·L<sup>-1</sup>]. The rate of concentration change is  $dc_B/dt$  [(mol·L<sup>-1</sup>)·s<sup>-1</sup>], where  
1356 concentration is  $c_B = n_B/V$ . There is a difference between (1)  $J_{V,rO_2}$  [mol·s<sup>-1</sup>·L<sup>-1</sup>] and (2) rate of  
1357 concentration change [mol·L<sup>-1</sup>·s<sup>-1</sup>]. These merge to a single expression only in closed systems.  
1358 In open systems, external fluxes (such as  $O_2$  supply) are distinguished from internal  
1359 transformations (catabolic flux,  $O_2$  consumption). In a closed system, external flows of all  
1360 substances are zero and  $O_2$  consumption (internal flow of catabolic reactions  $k$ ),  $I_{kO_2}$  [pmol·s<sup>-1</sup>],  
1361 causes a decline of the amount of  $O_2$  in the system,  $n_{O_2}$  [nmol]. Normalization of these quantities  
1362 for the volume of the system,  $V$  [L  $\equiv$  dm<sup>3</sup>], yields volume-specific  $O_2$  flux,  $J_{V,kO_2} = I_{kO_2}/V$   
1363 [nmol·s<sup>-1</sup>·L<sup>-1</sup>], and  $O_2$  concentration,  $[O_2]$  or  $c_{O_2} = n_{O_2}/V$  [ $\mu$ mol·L<sup>-1</sup> =  $\mu$ M = nmol·mL<sup>-1</sup>].  
1364 Instrumental background  $O_2$  flux is due to external flux into a non-ideal closed respirometer;  
1365 then total volume-specific flux has to be corrected for instrumental background  $O_2$  flux— $O_2$   
1366 diffusion into or out of the instrumental chamber.  $J_{V,kO_2}$  is relevant mainly for methodological  
1367 reasons and should be compared with the accuracy of instrumental resolution of background-  
1368 corrected flux, e.g.,  $\pm 1$  nmol·s<sup>-1</sup>·L<sup>-1</sup> (Gnaiger 2001). ‘Metabolic’ or catabolic indicates  $O_2$  flux,  
1369  $J_{kO_2}$ , corrected for: (1) instrumental background  $O_2$  flux; (2) chemical background  $O_2$  flux due  
1370 to autoxidation of chemical components added to the incubation medium; and (3) *Rox* for  $O_2$ -  
1371 consuming side reactions unrelated to the catabolic pathway  $k$ .

## 1372 1373 1374 6. Conversion of units

1375  
1376 Many different units have been used to report the  $O_2$  consumption rate, OCR (Table 6).  
1377 *SI* base units provide the common reference to introduce the theoretical principles (Figure 7),  
1378 and are used with appropriately chosen *SI* prefixes to express numerical data in the most  
1379 practical format, with an effort towards unification within specific areas of application (Table  
1380 7). Reporting data in *SI* units—including the mole [mol], coulomb [C], joule [J], and second  
1381 [s]—should be encouraged, particularly by journals which propose the use of *SI* units.

1382 Although volume is expressed as m<sup>3</sup> using the *SI* base unit, the litre [dm<sup>3</sup>] is a  
1383 conventional unit of volume for concentration and is used for most solution chemical kinetics.  
1384 If one multiplies  $I_{O_2/Nce}$  by  $C_{Nce}$ , then the result will not only be the amount of  $O_2$  [mol]  
1385 consumed per time [s<sup>-1</sup>] in one litre [L<sup>-1</sup>], but also the change in  $O_2$  concentration per second  
1386 (for any volume of an ideally closed system). This is ideal for kinetic modeling as it blends with  
1387 chemical rate equations where concentrations are typically expressed in mol·L<sup>-1</sup> (Wagner *et al.*  
1388 2011). In studies of multinuclear cells—such as differentiated skeletal muscle cells—it is easy

1389 to determine the number of nuclei but not the total number of cells. A generalized concept,  
1390 therefore, is obtained by substituting cells by nuclei as the sample entity. This does not hold,  
1391 however, for enucleated platelets.

1392

1393 **Table 6. Conversion of various formats and units used in respirometry and**  
1394 **ergometry.**  $e^-$  is the number of electrons or reducing equivalents.  $z_B$  is the charge  
1395 number of entity B.

1396

Format	1 Unit		Multiplication factor	SI-unit	Note
$\underline{n}$	ng.atom O $\cdot$ s $^{-1}$	(2 e $^-$ )	0.5	nmol O $_2$ $\cdot$ s $^{-1}$	
$\underline{n}$	ng.atom O $\cdot$ min $^{-1}$	(2 e $^-$ )	8.33	pmol O $_2$ $\cdot$ s $^{-1}$	
$\underline{n}$	natom O $\cdot$ min $^{-1}$	(2 e $^-$ )	8.33	pmol O $_2$ $\cdot$ s $^{-1}$	
$\underline{n}$	nmol O $_2$ $\cdot$ min $^{-1}$	(4 e $^-$ )	16.67	pmol O $_2$ $\cdot$ s $^{-1}$	
$\underline{n}$	nmol O $_2$ $\cdot$ h $^{-1}$	(4 e $^-$ )	0.2778	pmol O $_2$ $\cdot$ s $^{-1}$	
$\underline{V}$ to $\underline{n}$	mL O $_2$ $\cdot$ min $^{-1}$ at STPD $^a$		0.744	$\mu$ mol O $_2$ $\cdot$ s $^{-1}$	1
$\underline{e}$ to $\underline{n}$	W = J/s at -470 kJ/mol O $_2$		-2.128	$\mu$ mol O $_2$ $\cdot$ s $^{-1}$	
$\underline{e}$ to $\underline{n}$	mA = mC $\cdot$ s $^{-1}$	( $z_{H^+} = 1$ )	10.36	nmol H $^+$ $\cdot$ s $^{-1}$	2
$\underline{e}$ to $\underline{n}$	mA = mC $\cdot$ s $^{-1}$	( $z_{O_2} = 4$ )	2.59	nmol O $_2$ $\cdot$ s $^{-1}$	2
$\underline{n}$ to $\underline{e}$	nmol H $^+$ $\cdot$ s $^{-1}$	( $z_{H^+} = 1$ )	0.09649	mA	3
$\underline{n}$ to $\underline{e}$	nmol O $_2$ $\cdot$ s $^{-1}$	( $z_{O_2} = 4$ )	0.38594	mA	3

1397 1 At standard temperature and pressure dry (STPD: 0 °C = 273.15 K and 1 atm = 101.325  
1398 kPa = 760 mmHg), the molar volume of an ideal gas,  $V_m$ , and  $V_{m,O_2}$  is 22.414 and 22.392  
1399 L $\cdot$ mol $^{-1}$ , respectively. Rounded to three decimal places, both values yield the conversion  
1400 factor of 0.744. For comparison at normal temperature and pressure dry (NTPD: 20 °C),  
1401  $V_{m,O_2}$  is 24.038 L $\cdot$ mol $^{-1}$ . Note that the SI standard pressure is 100 kPa.

1402 2 The multiplication factor is  $10^6/(z_B \cdot F)$ .

1403 3 The multiplication factor is  $z_B \cdot F/10^6$ .

1404

1405 For studies of cells, we recommend that respiration be expressed, as far as possible, as:  
1406 (1) O $_2$  flux normalized for a mitochondrial marker, for separation of the effects of mitochondrial  
1407 quality and content on cell respiration (this includes FCRs as a normalization for a functional  
1408 mitochondrial marker); (2) O $_2$  flux in units of cell volume or mass, for comparison of respiration  
1409 of cells with different cell size (Renner *et al.* 2003) and with studies on tissue preparations, and  
1410 (3) O $_2$  flow in units of attomole ( $10^{-18}$  mol) of O $_2$  consumed in a second by each cell  
1411 [amol $\cdot$ s $^{-1}$  $\cdot$ cell $^{-1}$ ], numerically equivalent to [pmol $\cdot$ s $^{-1}$  $\cdot$ 10 $^{-6}$  cells]. This convention allows  
1412 information to be easily used when designing experiments in which O $_2$  flow must be considered.  
1413 For example, to estimate the volume-specific O $_2$  flux in an instrument chamber that would be  
1414 expected at a particular cell number concentration, one simply needs to multiply the flow per  
1415 cell by the number of cells per volume of interest. This provides the amount of O $_2$  [mol]  
1416 consumed per time [s $^{-1}$ ] per unit volume [L $^{-1}$ ]. At an O $_2$  flow of 100 amol $\cdot$ s $^{-1}$  $\cdot$ cell $^{-1}$  and a cell  
1417 density of 10 $^9$  cells $\cdot$ L $^{-1}$  (10 $^6$  cells $\cdot$ mL $^{-1}$ ), the volume-specific O $_2$  flux is 100 nmol $\cdot$ s $^{-1}$  $\cdot$ L $^{-1}$  (100  
1418 pmol $\cdot$ s $^{-1}$  $\cdot$ mL $^{-1}$ ).

1419 ET-capacity in human cell types including HEK 293, primary HUVEC and fibroblasts  
1420 ranges from 50 to 180 amol $\cdot$ s $^{-1}$  $\cdot$ cell $^{-1}$ , measured in intact cells in the noncoupled state (see  
1421 Gnaiger 2014). At 100 amol $\cdot$ s $^{-1}$  $\cdot$ cell $^{-1}$  corrected for  $R_{ox}$ , the current across the mt-membranes,  
1422  $I_{H^+e}$ , approximates 193 pA $\cdot$ cell $^{-1}$  or 0.2 nA per cell. See Rich (2003) for an extension of  
1423 quantitative bioenergetics from the molecular to the human scale, with a transmembrane proton  
1424 flux equivalent to 520 A in an adult at a catabolic power of -110 W. Modelling approaches  
1425 illustrate the link between protonmotive force and currents (Willis *et al.* 2016).

1426

**Table 7. Conversion of units with preservation of numerical values.**

Name	Frequently used unit	Equivalent unit	Note
volume-specific flux, $J_{V,O_2}$	$\text{pmol}\cdot\text{s}^{-1}\cdot\text{mL}^{-1}$ $\text{mmol}\cdot\text{s}^{-1}\cdot\text{L}^{-1}$	$\text{nmol}\cdot\text{s}^{-1}\cdot\text{L}^{-1}$ $\text{mol}\cdot\text{s}^{-1}\cdot\text{m}^{-3}$	1
cell-specific flow, $I_{O_2/\text{cell}}$	$\text{pmol}\cdot\text{s}^{-1}\cdot 10^{-6}$ cells	$\text{amol}\cdot\text{s}^{-1}\cdot\text{cell}^{-1}$	2
	$\text{pmol}\cdot\text{s}^{-1}\cdot 10^{-9}$ cells	$\text{zmol}\cdot\text{s}^{-1}\cdot\text{cell}^{-1}$	3
cell number concentration, $C_{Nce}$	$10^6$ cells $\cdot\text{mL}^{-1}$	$10^9$ cells $\cdot\text{L}^{-1}$	
mitochondrial protein concentration, $C_{mtE}$	$0.1$ mg $\cdot\text{mL}^{-1}$	$0.1$ g $\cdot\text{L}^{-1}$	
mass-specific flux, $J_{O_2/m}$	$\text{pmol}\cdot\text{s}^{-1}\cdot\text{mg}^{-1}$	$\text{nmol}\cdot\text{s}^{-1}\cdot\text{g}^{-1}$	4
catabolic power, $P_k$	$\mu\text{W}\cdot 10^{-6}$ cells	$\text{pW}\cdot\text{cell}^{-1}$	1
Volume	1,000 L	$\text{m}^3$ (1,000 kg)	
	L	$\text{dm}^3$ (kg)	
	mL	$\text{cm}^3$ (g)	
	$\mu\text{L}$	$\text{mm}^3$ (mg)	
	fL	$\mu\text{m}^3$ (pg)	5
amount of substance concentration	$\text{M} = \text{mol}\cdot\text{L}^{-1}$	$\text{mol}\cdot\text{dm}^{-3}$	

1427

1428 1 pmol: picomole =  $10^{-12}$  mol1429 2 amol: attomole =  $10^{-18}$  mol1430 3 zmol: zeptomole =  $10^{-21}$  mol

1431

1432 We consider isolated mitochondria as powerhouses and proton pumps as molecular  
 1433 machines to relate experimental results to energy metabolism of the intact cell. The cellular  
 1434  $P_{\gg}/O_2$  based on oxidation of glycogen is increased by the glycolytic (fermentative) substrate-  
 1435 level phosphorylation of 3  $P_{\gg}/\text{Glyc}$  or 0.5 mol  $P_{\gg}$  for each mol  $O_2$  consumed in the complete  
 1436 oxidation of a mol glycosyl unit (Glyc). Adding 0.5 to the mitochondrial  $P_{\gg}/O_2$  ratio of 5.4  
 1437 yields a bioenergetic cell physiological  $P_{\gg}/O_2$  ratio close to 6. Two NADH equivalents are  
 1438 formed during glycolysis and transported from the cytosol into the mitochondrial matrix, either  
 1439 by the malate-aspartate shuttle or by the glycerophosphate shuttle (**Figure 2A**) resulting in  
 1440 different theoretical yields of ATP generated by mitochondria, the energetic cost of which  
 1441 potentially must be taken into account. Considering also substrate-level phosphorylation in the  
 1442 TCA cycle, this high  $P_{\gg}/O_2$  ratio not only reflects proton translocation and OXPHOS studied  
 1443 in isolation, but integrates mitochondrial physiology with energy transformation in the living  
 1444 cell (Gnaiger 1993a).

1445

1446

1447 **7. Conclusions**

1448

1449 Catabolic cell respiration is the process of exergonic and exothermic energy  
 1450 transformation in which scalar redox reactions are coupled to vectorial ion translocation across  
 1451 a semipermeable membrane, which separates the small volume of a bacterial cell or  
 1452 mitochondrion from the larger volume of its surroundings. The electrochemical exergy can be  
 1453 partially conserved in the phosphorylation of ADP to ATP or in ion pumping, or dissipated in  
 1454 an electrochemical short-circuit. Respiration is thus clearly distinguished from fermentation as  
 1455 the counterpart of cellular core energy metabolism. An  $O_2$  flux balance scheme illustrates the  
 1456 relationships and general definitions (**Figures 1 and 2**).

1457 Experimentally, respiration is separated in mitochondrial preparations from the  
 1458 interactions with the fermentative pathways of the intact cell. OXPHOS analysis (**Figure 3**) is  
 1459 based on the study of mitochondrial preparations complementary to bioenergetic investigations



1460 of intact cells and organisms—from model organisms to the human species including healthy  
 1461 and diseased persons (patients). Different mechanisms of respiratory uncoupling have to be  
 1462 distinguished (**Figure 4**). Metabolic fluxes measured in defined coupling and pathway control  
 1463 states (**Figures 5 and 6**) provide insights into the meaning of cellular and organismic  
 1464 respiration.

1465 The optimal choice for expressing mitochondrial and cell respiration as O<sub>2</sub> flow per  
 1466 biological sample, and normalization for specific tissue-markers (volume, mass, protein) and  
 1467 mitochondrial markers (volume, protein, content, mtDNA, activity of marker enzymes,  
 1468 respiratory reference state) is guided by the scientific question under study. Interpretation of  
 1469 the data depends critically on appropriate normalization (**Figure 7**).

1470 MitoEAGLE can serve as a gateway to better diagnose mitochondrial respiratory  
 1471 adaptations and defects linked to genetic variation, age-related health risks, sex-specific  
 1472 mitochondrial performance, lifestyle with its effects on degenerative diseases, and thermal and  
 1473 chemical environment. The present recommendations on coupling control states and rates,  
 1474 linked to the concept of the protonmotive force, are focused on studies with mitochondrial  
 1475 preparations (**Box 3**). These will be extended in a series of reports on pathway control of  
 1476 mitochondrial respiration, respiratory states in intact cells, and harmonization of experimental  
 1477 procedures.

1478

---

### 1479 **Box 3: Recommendations for studies with mitochondrial preparations**

1480

- 1481 ● Normalization of respiratory rates should be provided as far as possible:

1482

1. *Biophysical normalization*: on a per cell basis as O<sub>2</sub> flow; this may not be possible when dealing with coenocytic organisms or tissues without cross-walls separating individual cells (*e.g.*, filamentous fungi, muscle fibers)

1483

2. *Cellular normalization*: per g protein; per cell- or tissue-mass as mass-specific O<sub>2</sub> flux; per cell volume as cell volume-specific flux

1484

3. *Mitochondrial normalization*: per mitochondrial marker as mt-specific flux.

1485

1486

1487

1488 With information on cell size and the use of multiple normalizations, maximum potential  
 1489 information is available (Renner *et al.* 2003; Wagner *et al.* 2011; Gnaiger 2014). Reporting  
 1490 flow in a respiratory chamber [nmol·s<sup>-1</sup>] is discouraged, since it restricts the analysis to intra-  
 1491 experimental comparison of relative (qualitative) differences.

1488

1489

1490

1491

- 1492 ● Catabolic mitochondrial respiration is distinguished from residual O<sub>2</sub> consumption. Fluxes  
 1493 in mitochondrial coupling states should be, as far as possible, corrected for residual O<sub>2</sub>  
 1494 consumption.

1492

1493

1494

- 1495 ● Different mechanisms of uncoupling should be distinguished by defined terms. The tightness  
 1496 of coupling relates to these uncoupling mechanisms, whereas the coupling stoichiometry  
 1497 varies as a function the substrate type involved in ET-pathways with either three or two  
 1498 redox proton pumps operating in series. Separation of tightness of coupling from the  
 1499 pathway-dependent coupling stoichiometry is possible only when the substrate type  
 1500 undergoing oxidation remains the same for respiration in LEAK-, OXPHOS-, and ET-states.  
 1501 In studies of the tightness of coupling, therefore, simple substrate-inhibitor combinations  
 1502 should be applied to exclude a shift in substrate competition which may occur when  
 1503 providing physiological substrate cocktails.

1495

1496

1497

1498

1499

1500

1501

1502

1503

- 1504 ● In studies of isolated mitochondria, the mitochondrial recovery and yield should be reported.  
 1505 Experimental criteria for evaluation of purity versus integrity should be considered.  
 1506 Mitochondrial markers—such as citrate synthase activity as an enzymatic matrix marker—  
 1507 provide a link to the tissue of origin on the basis of calculating the mitochondrial recovery,  
 1508 *i.e.*, the fraction of mitochondrial marker obtained from a unit mass of tissue. Total  
 1509 mitochondrial protein is frequently applied as a mitochondrial marker, which is restricted to  
 1510 isolated mitochondria.

1504

1505

1506

1507

1508

1509

1510

- 1511 • In studies of permeabilized cells, the viability of the cell culture or cell suspension of origin  
 1512 should be reported. Normalization should be evaluated for total cell count or viable cell  
 1513 count.
- 1514 • Terms and symbols are summarized in **Table 8**. Their use will facilitate transdisciplinary  
 1515 communication and support further developments towards a consistent theory of  
 1516 bioenergetics and mitochondrial physiology. Technical terms related to and defined with  
 1517 normal words can be used as index terms in databases, support the creation of ontologies  
 1518 towards semantic information processing (MitoPedia), and help in communicating analytical  
 1519 findings as impactful data-driven stories. ‘*Making data available without making it*  
 1520 *understandable may be worse than not making it available at all*’ (National Academies of  
 1521 Sciences, Engineering, and Medicine 2018). Success will depend on taking next steps: (1)  
 1522 exhaustive text-mining considering Omics data and functional data; (2) network analysis of  
 1523 Omics data with bioinformatics tools; (3) cross-validation with distinct bioinformatics  
 1524 approaches; (4) correlation with functional data; (5) guidelines for biological validation of  
 1525 network data. This is a call to carefully contribute to FAIR principles (Findable, Accessible,  
 1526 Interoperable, Reusable) for the sharing of scientific data.

1528  
 1529  
 1530 **Table 8. Terms, symbols, and units.**

Term	Symbol	Unit	Links and comments
1531 alternative quinol oxidase	AOX		Figure 2B
1532 amount of substance B	$n_B$	[mol]	
1533 ATP yield per O <sub>2</sub>	$Y_{P\gg/O_2}$		P $\gg$ /O <sub>2</sub> ratio measured in any respiratory state
1534 catabolic reaction	k		Figure 1 and 3
1535 catabolic respiration	$J_{kO_2}$	<i>varies</i>	Figure 1 and 3
1536 cell number	$N_{ce}$	[x]	Table 5; $N_{ce} = N_{vce} + N_{dce}$
1537 cell respiration	$J_{rO_2}$	<i>varies</i>	Figure 1
1538 cell viability index	VI		$VI = N_{vce}/N_{ce} = 1 - N_{dce}/N_{ce}$
1539 Complexes I to IV	CI to CIV		respiratory ET Complexes; Figure 2B
1540 concentration of substance B	$c_B = n_B \cdot V^{-1}$ ; [B]	[mol·m <sup>-3</sup> ]	Box 2
1541 dead cell number	$N_{dce}$	[x]	Table 5; non-viable cells, loss of plasma membrane barrier function
1542 electric format	$e$	[C]	Table 6
1543 electron transfer system	ETS		Figure 2B, Figure 5; state
1544 flow, for substance B	$I_B$	[mol·s <sup>-1</sup> ]	system-related extensive quantity; Figure 7
1545 flux, for substance B	$J_B$	<i>varies</i>	size-specific quantity; Figure 7
1546 inorganic phosphate	P <sub>i</sub>		Figure 3
1547 intact cell number, viable cell number	$N_{vce}$	[x]	Table 5; viable cells, intact of plasma membrane barrier function
1548 LEAK	LEAK		Table 1, Figure 5; state
1549 mass format	$m$	[kg]	Table 4, Figure 7
1550 mass of sample X	$m_X$	[kg]	Table 4
1551 mass of entity X	$M_X$	[kg]	mass of object X; Table 4
1552 MITOCARTA			<a href="https://www.broadinstitute.org/scientific-community/science/programs/metabolic-disease-program/publications/mitocarta/mitocarta-in-0">https://www.broadinstitute.org/scientific-community/science/programs/metabolic-disease-program/publications/mitocarta/mitocarta-in-0</a>
1553 MitoPedia			<a href="http://www.bioblast.at/index.php/MitoPedia">http://www.bioblast.at/index.php/MitoPedia</a>
1554 mitochondria or mitochondrial	mt		Box 1
1555 mitochondrial DNA	mtDNA		Box 1
1556 mitochondrial concentration	$C_{mtE} = mtE \cdot V^{-1}$	[mtEU·m <sup>-3</sup> ]	Table 4

1570	mitochondrial content	$mtE_X = mtE \cdot N_X^{-1}$	[mtEU·x <sup>-1</sup> ]	Table 4
1571	mitochondrial elementary component	$mtE$	[mtEU]	Table 4, quantity of mt-marker
1572	mitochondrial elementary unit	mtEU	<i>varies</i>	Table 4, specific units for mt-marker
1573	mitochondrial inner membrane	mtIM		Figure 2; MIM is widely used; the first M is replaced by mt; Box 1
1574				
1575	mitochondrial outer membrane	mtOM		Figure 2; MOM is widely used; the first M is replaced by mt; Box 1
1576				
1577	mitochondrial recovery	$Y_{mtE}$		fraction of $mtE$ recovered in sample from the tissue of origin
1578				
1579	mitochondrial yield	$Y_{mtE/\underline{m}}$		mt-yield per tissues mass; $Y_{mtE/\underline{m}} = Y_{mtE} \cdot D_{mtE}$
1580				
1581	molar format	$\underline{n}$	[mol]	Table 6
1582	negative	neg		Figure 3
1583	number concentration of $X$	$C_{NX}$	[x·m <sup>-3</sup> ]	Table 4
1584	number format	$\underline{N}$	[x]	Table 4, Figure 7
1585	number of entities $X$	$N_X$	[x]	Table 4, Figure 7
1586	number of entity B	$N_B$	[x]	Table 4
1587	oxidative phosphorylation	OXPPOS		Table 1, Figure 5; state
1588	oxygen concentration	$c_{O_2} = n_{O_2} \cdot V^{-1}$ ; [O <sub>2</sub> ]	[mol·m <sup>-3</sup> ]	Section 3.2
1589	oxygen flux, in reaction r	$J_{rO_2}$	<i>varies</i>	Figure 1
1590	permeabilized cell number	$N_{pce}$	[x]	Table 5; experimental permeabilization of plasma membrane; $N_{pce} = N_{ce}$
1591				
1592	phosphorylation of ADP to ATP	P»		Section 2.2
1593	positive	pos		Figure 3
1594	proton in the negative compartment	H <sup>+</sup> <sub>neg</sub>		Figure 3
1595	proton in the positive compartment	H <sup>+</sup> <sub>pos</sub>		Figure 3
1596	rate of electron transfer in ET state	$E$		ET-capacity; Table 1
1597	rate of LEAK respiration	$L$		Table 1
1598	rate of oxidative phosphorylation	$P$		OXPPOS capacity; Table 1
1599	rate of residual oxygen consumption	$RoX$		Table 1, Figure 1
1600	residual oxygen consumption	ROX		Table 1; state
1601	respiratory supercomplex	SC I <sub>n</sub> III <sub>n</sub> IV <sub>n</sub>		Box 1; supramolecular assemblies composed of variable copy numbers ( $n$ ) of CI, CIII and CIV
1602				
1603				
1604	specific mitochondrial density	$D_{mtE} = mtE \cdot m_X^{-1}$	[mtEU·kg <sup>-1</sup> ]	Table 4
1605	volume	$V$	[m <sup>-3</sup> ]	Table 7
1606	volume format	$\underline{V}$	[m <sup>-3</sup> ]	Table 6
1607	weight, dry weight	$W_d$	[kg]	used as mass of sample $X$ ; Figure 7
1608	weight, wet weight	$W_w$	[kg]	used as mass of sample $X$ ; Figure 7
1609				

1610

## 1611 Acknowledgements

1612 We thank M. Beno for management assistance. This publication is based upon work from  
 1613 COST Action CA15203 MitoEAGLE, supported by COST (European Cooperation in Science  
 1614 and Technology), and K-Regio project MitoFit (E.G.).

1615

1616 **Competing financial interests:** E.G. is founder and CEO of Oroboros Instruments, Innsbruck,  
 1617 Austria.

1618

## 1619 References

1620

1621 Altmann R (1894) Die Elementarorganismen und ihre Beziehungen zu den Zellen. Zweite vermehrte Auflage.  
 1622 Verlag Von Veit & Comp, Leipzig:160 pp.

1623 Baggeto LG, Testa-Perussini R (1990) Role of acetoin on the regulation of intermediate metabolism of Ehrlich  
 1624 ascites tumor mitochondria: its contribution to membrane cholesterol enrichment modifying passive proton  
 1625 permeability. Arch Biochem Biophys 283:341-8.

1626 Beard DA (2005) A biophysical model of the mitochondrial respiratory system and oxidative phosphorylation.  
 1627 PLoS Comput Biol 1(4):e36.

1628 Benda C (1898) Weitere Mitteilungen über die Mitochondria. Verh Dtsch Physiol Ges:376-83.

- 1629 Birkedal R, Laasmaa M, Vendelin M (2014) The location of energetic compartments affects energetic  
1630 communication in cardiomyocytes. *Front Physiol* 5:376.
- 1631 Blier PU, Dufresne F, Burton RS (2001) Natural selection and the evolution of mtDNA-encoded peptides:  
1632 evidence for intergenomic co-adaptation. *Trends Genet* 17:400-6.
- 1633 Blier PU, Guderley HE (1993) Mitochondrial activity in rainbow trout red muscle: the effect of temperature on  
1634 the ADP-dependence of ATP synthesis. *J Exp Biol* 176:145-58.
- 1635 Breton S, Beaupré HD, Stewart DT, Hoeh WR, Blier PU (2007) The unusual system of doubly uniparental  
1636 inheritance of mtDNA: isn't one enough? *Trends Genet* 23:465-74.
- 1637 Brown GC (1992) Control of respiration and ATP synthesis in mammalian mitochondria and cells. *Biochem J*  
1638 284:1-13.
- 1639 Calvo SE, Klauser CR, Mootha VK (2016) MitoCarta2.0: an updated inventory of mammalian mitochondrial  
1640 proteins. *Nucleic Acids Research* 44:D1251-7.
- 1641 Calvo SE, Julien O, Clauser KR, Shen H, Kamer KJ, Wells JA, Mootha VK (2017) Comparative analysis of  
1642 mitochondrial N-termini from mouse, human, and yeast. *Mol Cell Proteomics* 16:512-23.
- 1643 Campos JC, Queliconi BB, Bozi LHM, Bechara LRG, Dourado PMM, Andres AM, Jannig PR, Gomes KMS,  
1644 Zambelli VO, Rocha-Resende C, Guatimosim S, Brum PC, Mochly-Rosen D, Gottlieb RA, Kowaltowski AJ,  
1645 Ferreira JCB (2017) Exercise reestablishes autophagic flux and mitochondrial quality control in heart failure.  
1646 *Autophagy* 13:1304-317.
- 1647 Canton M, Luvisetto S, Schmehl I, Azzone GF (1995) The nature of mitochondrial respiration and  
1648 discrimination between membrane and pump properties. *Biochem J* 310:477-81.
- 1649 Carrico C, Meyer JG, He W, Gibson BW, Verdin E (2018) The mitochondrial acylome emerges: proteomics,  
1650 regulation by Sirtuins, and metabolic and disease implications. *Cell Metab* 27:497-512.
- 1651 Chan DC (2006) Mitochondria: dynamic organelles in disease, aging, and development. *Cell* 125:1241-52.
- 1652 Chance B, Williams GR (1955a) Respiratory enzymes in oxidative phosphorylation. I. Kinetics of oxygen  
1653 utilization. *J Biol Chem* 217:383-93.
- 1654 Chance B, Williams GR (1955b) Respiratory enzymes in oxidative phosphorylation: III. The steady state. *J Biol*  
1655 *Chem* 217:409-27.
- 1656 Chance B, Williams GR (1955c) Respiratory enzymes in oxidative phosphorylation. IV. The respiratory chain. *J*  
1657 *Biol Chem* 217:429-38.
- 1658 Chance B, Williams GR (1956) The respiratory chain and oxidative phosphorylation. *Adv Enzymol Relat Subj*  
1659 *Biochem* 17:65-134.
- 1660 Chowdhury SK, Djordjevic J, Albensi B, Fernyhough P (2015) Simultaneous evaluation of substrate-dependent  
1661 oxygen consumption rates and mitochondrial membrane potential by TMRM and safranin in cortical  
1662 mitochondria. *Biosci Rep* 36:e00286.
- 1663 Cobb LJ, Lee C, Xiao J, Yen K, Wong RG, Nakamura HK, Mehta HH, Gao Q, Ashur C, Huffman DM, Wan J,  
1664 Muzumdar R, Barzilai N, Cohen P (2016) Naturally occurring mitochondrial-derived peptides are age-  
1665 dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. *Aging (Albany NY)* 8:796-  
1666 809.
- 1667 Cohen ER, Cvitas T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J,  
1668 Strauss HL, Takami M, Thor HL (2008) Quantities, units and symbols in physical chemistry, IUPAC Green  
1669 Book, 3rd Edition, 2nd Printing, IUPAC & RSC Publishing, Cambridge.
- 1670 Cooper H, Hedges LV, Valentine JC, eds (2009) The handbook of research synthesis and meta-analysis. Russell  
1671 Sage Foundation.
- 1672 Coopersmith J (2010) Energy, the subtle concept. The discovery of Feynman's blocks from Leibnitz to Einstein.  
1673 Oxford University Press:400 pp.
- 1674 Cummins J (1998) Mitochondrial DNA in mammalian reproduction. *Rev Reprod* 3:172-82.
- 1675 Dai Q, Shah AA, Garde RV, Yonish BA, Zhang L, Medvitz NA, Miller SE, Hansen EL, Dunn CN, Price TM  
1676 (2013) A truncated progesterone receptor (PR-M) localizes to the mitochondrion and controls cellular  
1677 respiration. *Mol Endocrinol* 27:741-53.
- 1678 Daum B, Walter A, Horst A, Osiewacz HD, Kühlbrandt W (2013) Age-dependent dissociation of ATP synthase  
1679 dimers and loss of inner-membrane cristae in mitochondria. *Proc Natl Acad Sci U S A* 110:15301-6.
- 1680 Divakaruni AS, Brand MD (2011) The regulation and physiology of mitochondrial proton leak. *Physiology*  
1681 (Bethesda) 26:192-205.
- 1682 Doerrier C, Garcia-Souza LF, Krumschnabel G, Wohlfarter Y, Mészáros AT, Gnaiger E (2018) High-Resolution  
1683 Fluorescence Respirometry and OXPHOS protocols for human cells, permeabilized fibres from small biopsies of  
1684 muscle, and isolated mitochondria. *Methods Mol Biol* 1782 (Palmeira CM, Moreno AJ, eds): Mitochondrial  
1685 Bioenergetics, 978-1-4939-7830-4.
- 1686 Doskey CM, van 't Erve TJ, Wagner BA, Buettner GR (2015) Moles of a substance per cell is a highly  
1687 informative dosing metric in cell culture. *PLOS ONE* 10:e0132572.
- 1688 Drahota Z, Milerová M, Stieglarová A, Houstek J, Ostádal B (2004) Developmental changes of cytochrome c  
1689 oxidase and citrate synthase in rat heart homogenate. *Physiol Res* 53:119-22.

- 1690 Duarte FV, Palmeira CM, Rolo AP (2014) The role of microRNAs in mitochondria: small players acting wide.  
1691 Genes (Basel) 5:865-86.
- 1692 Ehinger JK, Morota S, Hansson MJ, Paul G, Elmér E (2015) Mitochondrial dysfunction in blood cells from  
1693 amyotrophic lateral sclerosis patients. *J Neurol* 262:1493-503.
- 1694 Ernster L, Schatz G (1981) Mitochondria: a historical review. *J Cell Biol* 91:227s-55s.
- 1695 Estabrook RW (1967) Mitochondrial respiratory control and the polarographic measurement of ADP:O ratios.  
1696 *Methods Enzymol* 10:41-7.
- 1697 Faber C, Zhu ZJ, Castellino S, Wagner DS, Brown RH, Peterson RA, Gates L, Barton J, Bickett M, Hagerty L,  
1698 Kimbrough C, Sola M, Bailey D, Jordan H, Elangbam CS (2014) Cardiolipin profiles as a potential  
1699 biomarker of mitochondrial health in diet-induced obese mice subjected to exercise, diet-restriction and  
1700 ephedrine treatment. *J Appl Toxicol* 34:1122-9.
- 1701 Fell D (1997) Understanding the control of metabolism. Portland Press.
- 1702 Forstner H, Gnaiger E (1983) Calculation of equilibrium oxygen concentration. In: Polarographic Oxygen  
1703 Sensors. Aquatic and Physiological Applications. Gnaiger E, Forstner H (eds), Springer, Berlin, Heidelberg,  
1704 New York:321-33.
- 1705 Garlid KD, Beavis AD, Ratkje SK (1989) On the nature of ion leaks in energy-transducing membranes. *Biochim*  
1706 *Biophys Acta* 976:109-20.
- 1707 Garlid KD, Semrad C, Zinchenko V. Does redox slip contribute significantly to mitochondrial respiration? In:  
1708 Schuster S, Rigoulet M, Ouhabi R, Mazat J-P, eds (1993) Modern trends in biothermokinetics. Plenum Press,  
1709 New York, London:287-93.
- 1710 Gerö D, Szabo C (2016) Glucocorticoids suppress mitochondrial oxidant production via upregulation of  
1711 uncoupling protein 2 in hyperglycemic endothelial cells. *PLoS One* 11:e0154813.
- 1712 Gnaiger E. Efficiency and power strategies under hypoxia. Is low efficiency at high glycolytic ATP production a  
1713 paradox? In: Surviving Hypoxia: Mechanisms of Control and Adaptation. Hochachka PW, Lutz PL, Sick T,  
1714 Rosenthal M, Van den Thillart G, eds (1993a) CRC Press, Boca Raton, Ann Arbor, London, Tokyo:77-109.
- 1715 Gnaiger E (1993b) Nonequilibrium thermodynamics of energy transformations. *Pure Appl Chem* 65:1983-2002.
- 1716 Gnaiger E (2001) Bioenergetics at low oxygen: dependence of respiration and phosphorylation on oxygen and  
1717 adenosine diphosphate supply. *Respir Physiol* 128:277-97.
- 1718 Gnaiger E (2009) Capacity of oxidative phosphorylation in human skeletal muscle. New perspectives of  
1719 mitochondrial physiology. *Int J Biochem Cell Biol* 41:1837-45.
- 1720 Gnaiger E (2014) Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 4th ed.  
1721 *Mitochondr Physiol Network* 19.12. Oroboros MiPNet Publications, Innsbruck:80 pp.
- 1722 Gnaiger E, Méndez G, Hand SC (2000) High phosphorylation efficiency and depression of uncoupled respiration  
1723 in mitochondria under hypoxia. *Proc Natl Acad Sci USA* 97:11080-5.
- 1724 Greggio C, Jha P, Kulkarni SS, Lagarrigue S, Broskey NT, Boutant M, Wang X, Conde Alonso S, Ofori E,  
1725 Auwerx J, Cantó C, Amati F (2017) Enhanced respiratory chain supercomplex formation in response to  
1726 exercise in human skeletal muscle. *Cell Metab* 25:301-11.
- 1727 Hinkle PC (2005) P/O ratios of mitochondrial oxidative phosphorylation. *Biochim Biophys Acta* 1706:1-11.
- 1728 Hofstadter DR (1979) Gödel, Escher, Bach: An eternal golden braid. A metaphorical fugue on minds and  
1729 machines in the spirit of Lewis Carroll. Harvester Press:499 pp.
- 1730 Illaste A, Laasmaa M, Peterson P, Vendelin M (2012) Analysis of molecular movement reveals latticelike  
1731 obstructions to diffusion in heart muscle cells. *Biophys J* 102:739-48.
- 1732 Jasienski M, Bazzaz FA (1999) The fallacy of ratios and the testability of models in biology. *Oikos* 84:321-26.
- 1733 Jepihhina N, Beraud N, Sepp M, Birkedal R, Vendelin M (2011) Permeabilized rat cardiomyocyte response  
1734 demonstrates intracellular origin of diffusion obstacles. *Biophys J* 101:2112-21.
- 1735 Klepinin A, Ounpuu L, Guzun R, Chekulayev V, Timohhina N, Tepp K, Shevchuk I, Schlattner U, Kaambre T  
1736 (2016) Simple oxygraphic analysis for the presence of adenylate kinase 1 and 2 in normal and tumor cells. *J*  
1737 *Bioenerg Biomembr* 48:531-48.
- 1738 Klingenberg M (2017) UCP1 - A sophisticated energy valve. *Biochimie* 134:19-27.
- 1739 Koit A, Shevchuk I, Ounpuu L, Klepinin A, Chekulayev V, Timohhina N, Tepp K, Puurand M, Truu L, Heck K,  
1740 Valvere V, Guzun R, Kaambre T (2017) Mitochondrial respiration in human colorectal and breast cancer  
1741 clinical material is regulated differently. *Oxid Med Cell Longev* 1372640.
- 1742 Komlódi T, Tretter L (2017) Methylene blue stimulates substrate-level phosphorylation catalysed by succinyl-  
1743 CoA ligase in the citric acid cycle. *Neuropharmacology* 123:287-98.
- 1744 Korn E (1969) Cell membranes: structure and synthesis. *Annu Rev Biochem* 38:263-88.
- 1745 Lane N (2005) Power, sex, suicide: mitochondria and the meaning of life. Oxford University Press:354 pp.
- 1746 Larsen S, Nielsen J, Neigaard Nielsen C, Nielsen LB, Wibrand F, Stride N, Schroder HD, Boushel RC, Helge  
1747 JW, Dela F, Hey-Mogensen M (2012) Biomarkers of mitochondrial content in skeletal muscle of healthy  
1748 young human subjects. *J Physiol* 590:3349-60.
- 1749 Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R,  
1750 Cohen P (2015) The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces  
1751 obesity and insulin resistance. *Cell Metab* 21:443-54.

- 1752 Lee SR, Kim HK, Song IS, Youm J, Dizon LA, Jeong SH, Ko TH, Heo HJ, Ko KS, Rhee BD, Kim N, Han J  
1753 (2013) Glucocorticoids and their receptors: insights into specific roles in mitochondria. *Prog Biophys Mol*  
1754 *Biol* 112:44-54.
- 1755 Leek BT, Mudaliar SR, Henry R, Mathieu-Costello O, Richardson RS (2001) Effect of acute exercise on citrate  
1756 synthase activity in untrained and trained human skeletal muscle. *Am J Physiol Regul Integr Comp Physiol*  
1757 280:R441-7.
- 1758 Lemieux H, Blier PU, Gnaiger E (2017) Remodeling pathway control of mitochondrial respiratory capacity by  
1759 temperature in mouse heart: electron flow through the Q-junction in permeabilized fibers. *Sci Rep* 7:2840.
- 1760 Lenaz G, Tioli G, Falasca AI, Genova ML (2017) Respiratory supercomplexes in mitochondria. In: *Mechanisms*  
1761 *of primary energy transduction in biology*. M Wikstrom (ed) Royal Society of Chemistry Publishing, London,  
1762 UK:296-337.
- 1763 Liu S, Roellig DM, Guo Y, Li N, Frace MA, Tang K, Zhang L, Feng Y, Xiao L (2016) Evolution of mitosome  
1764 metabolism and invasion-related proteins in *Cryptosporidium*. *BMC Genomics* 17:1006.
- 1765 Margulis L (1970) Origin of eukaryotic cells. New Haven: Yale University Press.
- 1766 Meinild Lundby AK, Jacobs RA, Gehrig S, de Leur J, Hauser M, Bonne TC, Flück D, Dandanell S, Kirk N,  
1767 Kaech A, Ziegler U, Larsen S, Lundby C (2018) Exercise training increases skeletal muscle mitochondrial  
1768 volume density by enlargement of existing mitochondria and not de novo biogenesis. *Acta Physiol* 222,  
1769 e12905.
- 1770 Menshikova EV, Ritov VB, Fairfull L, Ferrell RE, Kelley DE, Goodpaster BH (2006) Effects of exercise on  
1771 mitochondrial content and function in aging human skeletal muscle. *J Gerontol A Biol Sci Med Sci* 61:534-  
1772 40.
- 1773 Menshikova EV, Ritov VB, Ferrell RE, Azuma K, Goodpaster BH, Kelley DE (2007) Characteristics of skeletal  
1774 muscle mitochondrial biogenesis induced by moderate-intensity exercise and weight loss in obesity. *J Appl*  
1775 *Physiol* (1985) 103:21-7.
- 1776 Menshikova EV, Ritov VB, Toledo FG, Ferrell RE, Goodpaster BH, Kelley DE (2005) Effects of weight loss  
1777 and physical activity on skeletal muscle mitochondrial function in obesity. *Am J Physiol Endocrinol Metab*  
1778 288:E818-25.
- 1779 Miller GA (1991) The science of words. Scientific American Library New York:276 pp.
- 1780 Mitchell P (1961) Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of  
1781 mechanism. *Nature* 191:144-8.
- 1782 Mitchell P (2011) Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. *Biochim Biophys*  
1783 *Acta Bioenergetics* 1807:1507-38.
- 1784 Mogensen M, Sahlin K, Fernström M, Glintborg D, Vind BF, Beck-Nielsen H, Højlund K (2007) Mitochondrial  
1785 respiration is decreased in skeletal muscle of patients with type 2 diabetes. *Diabetes* 56:1592-9.
- 1786 Mohr PJ, Phillips WD (2015) Dimensionless units in the SI. *Metrologia* 52:40-7.
- 1787 Moreno M, Giacco A, Di Munno C, Goglia F (2017) Direct and rapid effects of 3,5-diiodo-L-thyronine (T2).  
1788 *Mol Cell Endocrinol* 7207:30092-8.
- 1789 Morrow RM, Picard M, Derbeneva O, Leipzig J, McManus MJ, Gouspillou G, Barbat-Artigas S, Dos Santos C,  
1790 Hepple RT, Murdock DG, Wallace DC (2017) Mitochondrial energy deficiency leads to hyperproliferation of  
1791 skeletal muscle mitochondria and enhanced insulin sensitivity. *Proc Natl Acad Sci U S A* 114:2705-10.
- 1792 Murley A, Nunnari J (2016) The emerging network of mitochondria-organelle contacts. *Mol Cell* 61:648-53.
- 1793 National Academies of Sciences, Engineering, and Medicine (2018) International coordination for science data  
1794 infrastructure: Proceedings of a workshop—in brief. Washington, DC: The National Academies Press. doi:  
1795 <https://doi.org/10.17226/25015>.
- 1796 Palmfeldt J, Bross P (2017) Proteomics of human mitochondria. *Mitochondrion* 33:2-14.
- 1797 Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G (2014) Functional role of cardiolipin in  
1798 mitochondrial bioenergetics. *Biochim Biophys Acta* 1837:408-17.
- 1799 Pesta D, Gnaiger E (2012) High-Resolution Respirometry. OXPHOS protocols for human cells and  
1800 permeabilized fibres from small biopsies of human muscle. *Methods Mol Biol* 810:25-58.
- 1801 Pesta D, Hoppel F, Macek C, Messner H, Faulhaber M, Kobel C, Parson W, Burtcher M, Schocke M, Gnaiger  
1802 E (2011) Similar qualitative and quantitative changes of mitochondrial respiration following strength and  
1803 endurance training in normoxia and hypoxia in sedentary humans. *Am J Physiol Regul Integr Comp Physiol*  
1804 301:R1078–87.
- 1805 Price TM, Dai Q (2015) The role of a mitochondrial progesterone receptor (PR-M) in progesterone action.  
1806 *Semin Reprod Med* 33:185-94.
- 1807 Puchowicz MA, Varnes ME, Cohen BH, Friedman NR, Kerr DS, Hoppel CL (2004) Oxidative phosphorylation  
1808 analysis: assessing the integrated functional activity of human skeletal muscle mitochondria – case studies.  
1809 *Mitochondrion* 4:377-85. Puntschart A, Claassen H, Jostarndt K, Hoppeler H, Billeter R (1995) mRNAs of  
1810 enzymes involved in energy metabolism and mtDNA are increased in endurance-trained athletes. *Am J*  
1811 *Physiol* 269:C619-25.
- 1812 Quiros PM, Mottis A, Auwerx J (2016) Mitonuclear communication in homeostasis and stress. *Nat Rev Mol*  
1813 *Cell Biol* 17:213-26.


- 1814 Rackham O, Mercer TR, Filipovska A (2012) The human mitochondrial transcriptome and the RNA-binding  
1815 proteins that regulate its expression. *WIREs RNA* 3:675–95.
- 1816 Reichmann H, Hoppeler H, Mathieu-Costello O, von Bergen F, Pette D (1985) Biochemical and ultrastructural  
1817 changes of skeletal muscle mitochondria after chronic electrical stimulation in rabbits. *Pflugers Arch* 404:1-  
1818 9.
- 1819 Renner K, Amberger A, Konwalinka G, Gnaiger E (2003) Changes of mitochondrial respiration, mitochondrial  
1820 content and cell size after induction of apoptosis in leukemia cells. *Biochim Biophys Acta* 1642:115-23.
- 1821 Rice DW, Alverson AJ, Richardson AO, Young GJ, Sanchez-Puerta MV, Munzinger J, Barry K, Boore JL,  
1822 Zhang Y, dePamphilis CW, Knox EB, Palmer JD (2016) Horizontal transfer of entire genomes via  
1823 mitochondrial fusion in the angiosperm *Amborella*. *Science* 342:1468-73.
- 1824 Rich P (2003) Chemiosmotic coupling: The cost of living. *Nature* 421:583.
- 1825 Rostovtseva TK, Sheldon KL, Hassanzadeh E, Monge C, Saks V, Bezrukov SM, Sackett DL (2008) Tubulin  
1826 binding blocks mitochondrial voltage-dependent anion channel and regulates respiration. *Proc Natl Acad Sci*  
1827 *USA* 105:18746-51.
- 1828 Rustin P, Parfait B, Chretien D, Bourgeron T, Djouadi F, Bastin J, Rötig A, Munnich A (1996) Fluxes of  
1829 nicotinamide adenine dinucleotides through mitochondrial membranes in human cultured cells. *J Biol Chem*  
1830 271:14785-90.
- 1831 Saks VA, Veksler VI, Kuznetsov AV, Kay L, Sikk P, Tiivel T, Tranqui L, Olivares J, Winkler K, Wiedemann F,  
1832 Kunz WS (1998) Permeabilised cell and skinned fiber techniques in studies of mitochondrial function in  
1833 vivo. *Mol Cell Biochem* 184:81-100.
- 1834 Salabei JK, Gibb AA, Hill BG (2014) Comprehensive measurement of respiratory activity in permeabilized cells  
1835 using extracellular flux analysis. *Nat Protoc* 9:421-38.
- 1836 Sazanov LA (2015) A giant molecular proton pump: structure and mechanism of respiratory complex I. *Nat Rev*  
1837 *Mol Cell Biol* 16:375-88.
- 1838 Schneider TD (2006) Claude Shannon: biologist. The founder of information theory used biology to formulate  
1839 the channel capacity. *IEEE Eng Med Biol Mag* 25:30-3.
- 1840 Schönfeld P, Dymkowska D, Wojtczak L (2009) Acyl-CoA-induced generation of reactive oxygen species in  
1841 mitochondrial preparations is due to the presence of peroxisomes. *Free Radic Biol Med* 47:503-9.
- 1842 Schultz J, Wiesner RJ (2000) Proliferation of mitochondria in chronically stimulated rabbit skeletal muscle--  
1843 transcription of mitochondrial genes and copy number of mitochondrial DNA. *J Bioenerg Biomembr* 32:627-  
1844 34.
- 1845 Spejger D (2016) Being right on Q: shaping eukaryotic evolution. *Biochem J* 473:4103-27.
- 1846 Sugiura A, Mattie S, Prudent J, McBride HM (2017) Newly born peroxisomes are a hybrid of mitochondrial and  
1847 ER-derived pre-peroxisomes. *Nature* 542:251-4.
- 1848 Simson P, Jepihhina N, Laasmaa M, Peterson P, Birkedal R, Vendelin M (2016) Restricted ADP movement in  
1849 cardiomyocytes: Cytosolic diffusion obstacles are complemented with a small number of open mitochondrial  
1850 voltage-dependent anion channels. *J Mol Cell Cardiol* 97:197-203.
- 1851 Stucki JW, Ineichen EA (1974) Energy dissipation by calcium recycling and the efficiency of calcium transport  
1852 in rat-liver mitochondria. *Eur J Biochem* 48:365-75.
- 1853 Tonkonogi M, Harris B, Sahlin K (1997) Increased activity of citrate synthase in human skeletal muscle after a  
1854 single bout of prolonged exercise. *Acta Physiol Scand* 161:435-6.
- 1855 Torralba D, Baixauli F, Sánchez-Madrid F (2016) Mitochondria know no boundaries: mechanisms and functions  
1856 of intercellular mitochondrial transfer. *Front Cell Dev Biol* 4:107. eCollection 2016.
- 1857 Vamecq J, Schepers L, Parmentier G, Mannaerts GP (1987) Inhibition of peroxisomal fatty acyl-CoA oxidase by  
1858 antimycin A. *Biochem J* 248:603-7.
- 1859 Waczulikova I, Habodaszova D, Cagalinec M, Ferko M, Ulicna O, Mateasik A, Sikurova L, Ziegelhöffer A  
1860 (2007) Mitochondrial membrane fluidity, potential, and calcium transients in the myocardium from acute  
1861 diabetic rats. *Can J Physiol Pharmacol* 85:372-81.
- 1862 Wagner BA, Venkataraman S, Buettner GR (2011) The rate of oxygen utilization by cells. *Free Radic Biol Med*  
1863 51:700-712.
- 1864 Wang H, Hiatt WR, Barstow TJ, Brass EP (1999) Relationships between muscle mitochondrial DNA content,  
1865 mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. *Eur J Appl Physiol*  
1866 *Occup Physiol* 80:22-7.
- 1867 Watt IN, Montgomery MG, Runswick MJ, Leslie AG, Walker JE (2010) Bioenergetic cost of making an  
1868 adenosine triphosphate molecule in animal mitochondria. *Proc Natl Acad Sci U S A* 107:16823-7.
- 1869 Weibel ER, Hoppeler H (2005) Exercise-induced maximal metabolic rate scales with muscle aerobic capacity. *J*  
1870 *Exp Biol* 208:1635–44.
- 1871 White DJ, Wolff JN, Pierson M, Gemmell NJ (2008) Revealing the hidden complexities of mtDNA inheritance.  
1872 *Mol Ecol* 17:4925–42.
- 1873 Wikström M, Hummer G (2012) Stoichiometry of proton translocation by respiratory complex I and its  
1874 mechanistic implications. *Proc Natl Acad Sci U S A* 109:4431-6.

1875 Williams EG, Wu Y, Jha P, Dubuis S, Blattmann P, Argmann CA, Houten SM, Amariuta T, Wolski W,  
 1876 Zamboni N, Aebersold R, Auwerx J (2016) Systems proteomics of liver mitochondria function. Science 352  
 1877 (6291):aad0189  
 1878 Willis WT, Jackman MR, Messer JI, Kuzmiak-Glancy S, Glancy B (2016) A simple hydraulic analog model of  
 1879 oxidative phosphorylation. Med Sci Sports Exerc 48:990-1000.  
 1880



# Mitochondrial respiratory states and rates:

## Building blocks of mitochondrial physiology



Part 1 - [www.mitoeagle.org/index.php/MitoEAGLE\\_preprint\\_2018-02-08](http://www.mitoeagle.org/index.php/MitoEAGLE_preprint_2018-02-08)

Gnaiger E<sup>1,2</sup>, corresponding author  
 355 co-authors, MitoEAGLE Working Group


<sup>1</sup>Medical University Innsbruck  
<sup>2</sup>Oroboros, Innsbruck, Austria

**Aims** Clarity of concept and consistency of nomenclature facilitate effective transdisciplinary communication, education, and ultimately further discovery.

Adhering to uniform standards and harmonizing the terminology concerning mitochondrial respiratory states and rates will support the development of databases of mitochondrial respiratory function in cells, tissues, and species.

**Summary** Recommendations on coupling control states and rates are focused on studies with mitochondrial preparations.

- Fig. 1:** Respiration is defined by O<sub>2</sub> flux balance.
- Fig. 2:** OXPHOS analysis is based on the study of mt- preparations. Metabolic fluxes measured in defined coupling and pathway control states provide insights into the meaning of cellular respiration.
- Fig. 3:** Interpretation of respiratory rates depends critically on appropriate normalization.




**Figure 1. From mitochondrial to external respiration**


Mitochondrial (mt) respiration is the oxidation of fuel substrates (electron donors) and reduction of O<sub>2</sub> catalysed by the electron transfer system, ETS:

- (a)** mt-catabolic respiration, excluding
- (b)** mt-residual oxygen consumption, *Rox*.
- (c)** Total cellular O<sub>2</sub> consumption, including mt-*Rox*,
- (d)** non-mt catabolic *Rox*, particularly by peroxisomal oxidases, and
- (e)** non-mt *Rox* unrelated to catabolism.

External respiration, including aerobic microbial respiration, and extracellular O<sub>2</sub> consumption.



MiPart by Odra Noel



**Figure 2. Respiratory states (ET, OXPHOS, LEAK) and corresponding rates (E, P, L)**

Table 1. Coupling states and residual oxygen consumption in mitochondrial preparations in relation to respiration- and phosphorylation-flux,  $J_{kO_2}$  and  $J_{pO_2}$ , and protonmotive force,  $\Delta p$ . Coupling states are established at kinetically-saturating concentrations of fuel substrates and O<sub>2</sub>.

State	$J_{kO_2}$	$J_{pO_2}$	$\Delta p$	Inducing factors	Limiting factors
LEAK	$L$ ; low, cation leak-dependent respiration	0	max.	proton leak, slip, and cation cycling	$J_{pO_2} = 0$ : (1) without ADP, $L_S$ ; (2) max. ATP/ADP ratio, $L_T$ ; or (3) inhibition of the phosphorylation-pathway, $L_{Oxy}$
OXPHOS	$P$ ; high, ADP-stimulated respiration	max.	high	kinetically-saturating [ADP] and [P <sub>i</sub> ]	$J_{kO_2}$ by phosphorylation-pathway; or $J_{kO_2}$ by ET-capacity
ET	$E$ ; max., noncoupled respiration	0	low	optimal external uncoupler concentration for max. $J_{O_2, E}$	$J_{kO_2}$ by ET-capacity
ROX	$Rox$ ; min., residual O <sub>2</sub> consumption	0	0	$J_{O_2, Rox}$ in non-ET-pathway oxidation reactions	inhibition of all ET-pathways; or absence of fuel substrates

**Figure 3. Normalization of rate**

**A:** Cell respiration is normalized for (1) the experimental **Sample** (flow per object, mass-specific flux, or cell-volume-specific flux); or (2) for methodological reasons for the **Chamber** volume.

**B: Flow per cell** [ $\text{amol O}_2 \cdot \text{s}^{-1} \cdot \text{cell}^{-1}$ ] is flux per chamber volume,  $J_V$  [ $\text{nmol O}_2 \cdot \text{s}^{-1} \cdot \text{L}^{-1}$ ], divided by cell concentration in the chamber,  $N_{ce}/V$  [ $\text{cells} \cdot \text{L}^{-1}$ ], which is **Number** analysis. In **Structure** analysis, aerobic cell performance is mt-quality (mt-specific flux, e.g., per citrate synthase, CS) times mt-quantity, or mt-function times mt-structure.